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Ovarian carcinoma is the most lethal gynecological malignancy. The high relapse and
mortality rates are attributable to late diagnosis and development of drug resistance.
Identifying novel prognostic and therapeutic targets for ovarian carcinoma is crucial
for improving patients' long-term survival rate.
Forkhead box protein M1 (FOXM1), which is a widely studied member of the FOX
superfamily of proteins, participates in cell proliferation and apoptosis affecting the
developmental function of many organs. Recently, there has been emerging evidence
supporting the biological significance of FOXM1 in carcinogenesis. Overexpression
of FOXM1 has been reported in multiple human malignancies including primary
II
breast cancer, lung cancer, prostate cancer, etc. However, whether FOXM1
participates in the development of ovarian cancer, with emphasis on the association
with clinicopathological parameters and chemoresistance, remains unknown. This
study aims at elucidating the functional role of FOXM1 in the tumorigenesis of
ovarian cancer.
Immunohistochemical study showed higher nuclear FOXM1 expression was
significantly associated with advanced stages of ovarian cancer (P=0.035). Though
not reaching statistical significance, FOXM1 overexpression displayed association
with serous histologic subtype, high grade cancers (poor differentiation) and
chemoresistance. Patients with a low FOXM1 level had a significantly longer overall
(P=0.019) and disease-free survival (P=0.014) than those with high FOXM1
expression. Multivariate progression analysis established high expression of FOXM1,
advanced cancer stages and poor histological differentiation (high grade) as
independent prognostic factors for short overall and disease-free survival.
Consistently, in vitro Transwell assays demonstrated transient knockdown of FOXM1
was capable of reducing SKOV-3 migration and invasion. Furthermore, paclitaxel
treatment down-regulated FOXM1 expression in the sensitive cell line but not the
resistant one. Immunofluorescence and flow cytometric analyses demonstrated
FOXM1 knockdown could enhance paclitaxel-mediated mitotic catastrophe in ovarian
cancer cells.
III
Recent attention has been drawn to the oncogenic roles of kinesin-like protein KIF2C
and p21-activated kinase 4 (PAK4) in human cancers. Interestingly, the expressions of
KIF2C and PAK4 altered in a similar pattern to FOXM1 expression upon paclitaxel
treatment by displaying down-regulation only in the paclitaxel sensitive cell line but
not the resistant one. FOXM1 silencing, qPCR, luciferase reporter assay and
chromatin immunoprecipitation confirmed KIF2C and PAK4 to be novel
transcriptional targets of FOXM1. Clonogenic assay showed KIF2C knockdown
could re-sensitize resistant cell line to paclitaxel treatment. Flow cytometry
demonstrated KIF2C silencing was able to increase the number of cells blocked at
G2/M cell cycle phase in sensitive cell line and raise the number of apoptotic cells in
resistant cell line. Up-regulations of miR-590 and miR-370 were also observed in a
panel of drug resistant ovarian and breast cancer cell lines. While ectopic expression
of miR-590 reduced FOXM1 expression, FOXM1 also seemed to be able to regulate
the expression of miR-590.
In summary, this study showed overexpression of FOXM1 in ovarian cancer
correlated with poor survival of patients and paclitaxel resistance. KIF2C and PAK4
were identified as novel transcriptional targets of FOXM1 implicated in
chemoresistance.
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1Chapter 1
Introduction: ovarian cancer
1.1 Epidemiology of ovarian cancer
Ovarian cancer is the fifth and the seventh major cause of cancer deaths among
females in the United States and Hong Kong respectively (Hong Kong Cancer
Registry, 2013; Reynolds & Moller, 2006). In fact, it is the most lethal among all
gynaecological malignancies, with more than 60% of the estimated new cases dying
of the disease annually (SEER Cancer Statistics Factsheets, 2013). Although the
incidence rate of ovarian cancer has remained fairly steady over 30 years in the
United States (Jemal et al., 2009), the rates are on the rise in Hong Kong and the
United Kingdom (Hong Kong Cancer Registry, 2013; UK Cancer Registry, 2013).
Age-standardized rates of ovarian cancer have also been showing an increasing trend
in China and Japan (Marugame & Hirabayashi, 2007).
1.2 Histologic subtypes of ovarian cancer
There are more than 30 different types of ovarian cancer which are identified based on
the type of cells from which they originate. Epithelial ovarian carcinomas initiate
from cells lining the outer surface of ovary and account for over 90% of all ovarian
cancers, while the remaining 10% arises from stromal or germ cells (Auersperg et al.,
2001). Epithelial ovarian cancers can be generally classified into five histologic
subtypes, namely endometrioid, mucinous, clear cell, serous and undifferentiated
2(Rosen et al., 2009).
Serous carcinoma is the most common type of epithelial ovarian cancer, accounting
for more than half of the diagnosed cases. Most serous carcinomas display papillary
and micropapillary structure with focal slit-like spaces, while glandular, solid and
trabecular architecture are also present (Soslow, 2008) (Figure 1.1A). Serous subtype
typically demonstrates columnar cells with pink cytoplasm, though polygonal
eosinophilic cells, clear cells and signet ring cells can also be observed (Che et al.,
2001).
Endometrioid carcinoma contributes to approximately 10% of all ovarian carcinomas
(Seidman et al., 2004). Endometrioid ovarian tumours resemble their endometrial
counterparts generally displaying tubules, solid, sheetlike growth and papillae
(Soslow, 2008) (Figure 1.1B). It has been suggested that most endometrioid cancers
can be associated with endometriosis, endometrioid borderline tumour or a
synchronous endometrial neoplasm of endometrioid type (Bell & Kurman, 2000; Roth
et al., 2003).
Representing approximately 5% of all ovarian carcinomas, the mucinous subtype
displays a limited range of histologic features and is among the most difficult ovarian
carcinomas for interpretation (Figure 1.1C). Approximately 20% of primary mucinous
tumours are borderline tumours, noninvasive or invasive carcinomas with the
3remainder being cystadenomas (Hart, 2005). Well-differentiated ovarian mucinous
carcinomas often show a labyrinthine pattern evident of expansile invasion (Soslow,
2008).
Clear cell carcinoma constitutes approximately 5% of all ovarian tumours (Seidman et
al., 2004). The clear cell subtype demonstrates a rather limited architecture with the
recognition of papillary, tubulocystic and solid varieties. Typical clear cell cancers are
characterized by hobnail cells with clear cytoplasm (Soslow, 2008) (Figure 1.1D). It
has been reported that more than half of clear cell carcinomas are associated with
endometriosis, particularly atypical endometriosis or endometriosis-associated
tumours (Soslow, 2008).
4Figure 1.1 Photomicrographs of A) Serous, B) Endometrioid, C) Mucinous and D)
Clear cell carcinomas of the ovary. Magnifications X200, haematoxylin-eosin (H&E)
stain (Original figure)
A B
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51.3 Stages of ovarian cancer
A detailed staging system of ovarian cancer has been outlined by the International
Federation of Obstetricians and Gynaecologists (FIGO) in order to identify the spread
of ovarian cancer at diagnosis. Briefly, stage 1 describes ovarian tumour confined to
one or both ovaries whereas stage 2 tumour involves one or both ovaries and has
extended into the pelvis. Stage 3 tumour involves one or both ovaries with
microscopically confirmed peritoneal metastasis outside the pelvis with or without
regional lymph node metastasis. Stage 4 cancer describes distant metastasis of tumour
beyond the peritoneal cavity to other body organs such as the liver (UK Cancer
Registry, 2012).
1.4 Risk factors for ovarian cancer
1.4.1 Age
The incidence rate of ovarian cancer is highest among women aged between 60 and
64 years (World Health Organization, 2013).
1.4.2 Ethnicity
Not surprisingly, the incidence rates of ovarian cancer vary among ethnic groups.
While highest incidence rates are observed in North America, Northern and Western
Europe, Asian nations such as China have the lowest incidence rates (Parkin et al.,
1999; Pisani et al., 2002). In a large cohort of case-control studies, it has been
suggested that white women tend to have higher incidence rates when compared to
6black women (John et al., 1993; Whittemore et al., 1992).
1.4.3 Dietary intake
The relationship between dietary intake and risk for contracting cancer has drawn
considerable research attention. For instance, high meat consumption may raise the
possibility of developing ovarian cancer (La Vecchia et al., 1987). Recently, Di Maso
et al reported dietary intake of red meat is significantly correlated with the risk of
ovarian cancer (Di Maso et al., 2013). However, the association between dietary fat
intake and ovarian cancer risk is not supported by other studies (Kushi et al., 1999). It
has been found that intake of preserved food is positively associated with the
incidence of epithelial ovarian cancer in southern Chinese women (Lee et al., 2013a).
Though not significant, intake of sugary drinks has also been suggested to be related
to increased risk of ovarian cancer (King et al., 2013). Interestingly, regular tea
consumption has been documented to be associated with a reduced risk of ovarian
cancer for southern Chinese females (Lee et al., 2013b). Although extensive studies
have been carried out to investigate the association between alcohol consumption and
ovarian cancer risk, no definitive conclusions can be drawn (King et al., 2013; Kuper
et al., 2000; Schouten et al., 2004). Similarly, the relationship between smoking and
ovarian cancer is also inconclusive with contradictory findings in different
populations (Marchbanks et al., 2000; Modugno et al., 2002; Pan et al., 2004; Terry et
al., 2003).
71.4.4 Breastfeeding
Breastfeeding has long been broadly advocated for its beneficial effects to the health
of the baby. Emerging findings have indicated breastfeeding may be associated with
the risk of ovarian cancer. Gwinn et al reported women who adopt breastfeeding
enjoy a reduced risk of developing ovarian cancer (Gwinn et al., 1990). This is
consistent with recent studies demonstrating an inverse correlation between the
duration of breastfeeding and the risk of ovarian cancer based on cohort and
case-control studies (Luan et al., 2013). However, contradictory findings have also
been shown regarding the duration of lactation and risk of ovarian cancer (Jordan et
al., 2007). Clearly, more studies are required in order to determine whether
breastfeeding offers protection against the development of ovarian cancer.
1.4.5 Parity
Pregnancy has been associated with the risk of ovarian cancer and it has been
documented each delivery could confer a 16% to 22% reduction in the risk of getting
ovarian cancer (Zografos et al., 2004). Although it was found that nulliparous females
have higher ovarian cancer risk than parous women (Bodelon et al., 2013), Ness et al
recently reported that anovulatory infertility does not appear to be associated with the
risk of ovarian cancer (Ness et al., 2002).
81.4.6 Obesity
Obesity has long been associated with a wide range of diseases including coronary
heart disease and diabetes mellitus. Recent studies suggested a positive correlation
between obesity and increased risk of ovarian cancer (Leitzmann et al., 2009;
Rodriguez et al., 2002). Intriguingly, obesity has been suggested to increase risk of
the less common histologic subtypes of ovarian cancer but not that of high-grade
invasive serous carcinomas (Olsen et al., 2013).
1.4.7 Oral contraceptives
Several studies have consistently demonstrated a reduced risk of sporadic as well as
familial ovarian cancer with the consumption of oral contraception (Walker et al.,
2002). The risk reduction is already eminent after a few months of use and the effect
persists for years after discontinuation. Although it has been reported oral
contraceptives may lower the risk of ovarian cancer in women with pathogenic
mutations in BRCA1 or BRCA2 gene (Narod et al., 1998), a separate case-control
study showed oral contraceptives could reduce the risk of ovarian cancer only in
non-carriers but not in carriers of a BRCA mutation (Rodriguez et al., 2001).
1.4.8 Hereditary ovarian cancer
Family history of ovarian cancer remains the most significant risk factor though
hereditary ovarian cancer only accounts for about 10% of the cases (Reynolds &
Moller, 2006). The lifetime risk estimate for individuals who have one first degree
9relative with ovarian cancer is much higher than the average population risk (Stratton
et al., 1998; Thompson & Easton, 2002). Individuals with more than one affected
relative have an estimate of 3 to 23% (Stratton et al., 1998; Thompson & Easton,
2002). Two types of ovarian cancer susceptibility genes have been identified: the
breast and ovarian cancer tumour suppressor genes (BRCA1 and BRCA2) and the
mismatch repair genes associated with Hereditary Nonpolyposis Colorectal Cancer
(HNPCC) syndrome (Daniilidis & Karagiannis, 2007).
BRCA1 and BRCA2 are tumour suppressor genes that play important roles in
transcriptional regulation, homologous recombination and DNA damage repair
(Turner et al., 2005). Not surprisingly, insertions or deletions and missense alterations
of BRCA1 and BRCA2 generating truncated protein product could eventually lead to
tumorigenesis (Honrado et al., 2005). Mutations in the BRCA1 gene are estimated to
confer a 30% lifetime risk of ovarian cancer up to the age of 60, while mutations in
BRCA2 are estimated to confer a risk of 27% up to the age of 70 (Breast Cancer
Linkage Consortium, 1999; Thompson & Easton, 2002).
While mutations in BRCA genes account for approximately 90% of hereditary ovarian
cancer cases, HNPCC syndrome is responsible for the remaining (Aarnio et al., 1999).
The mismatch repair genes confer an increased lifetime risk of ovarian cancer of
approximately 9 to 12% in addition to an elevated risk of endometrial cancer (Aarnio
et al., 1999; Farrell et al., 2006).
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1.4.9 Other factors
Regular physical activity is beneficial to the well being of an individual and has been
demonstrated to protect against a wide range of diseases. Although it is hypothesized
that physical activity may reduce the risk of ovarian cancer, Bertone et al reported a
small, insignificant decrease in the risk only for the highest category of vigorous
activity (Bertone et al., 2002).
Animal experiments suggest that circadian disruption may be associated with ovarian
cancer. In an attempt to evaluate potential association between nightshift work and
risk of ovarian cancer, Bhatti et al recently performed a population-based case-control
study and found that nightshift work is associated with an increased risk of invasive
and borderline tumours among women aged 50 or above (Bhatti et al., 2013).
Although it has been documented non-steroidal anti-inflammatory drugs enhance
apoptosis of ovarian cancer cell lines (Rodriguez-Burford et al., 2002), whether there
exists an association between commonly used anti-inflammatory drugs and risk of
ovarian cancer remains elusive due to a lack of observational studies. Among the few
related findings, aspirin consumption has been shown to be inversely associated with
epithelial ovarian cancer (Akhmedkhanov et al., 2001).
Hormone replacement therapy (HRT) has also been linked to ovarian cancer. Recently,
several studies consistently demonstrated an elevated risk of ovarian cancer for
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long-term users of oestrogen replacement therapy (Cramer et al., 2001; Riman et al.,
2002).
1.5 Genetic bases of epithelial ovarian cancer
Approximately 90% of all epithelial ovarian cancers belong to sporadic tumours
involving amplifications and mutations of a myriad of tumour suppressor genes and
oncogenes (Auersperg et al., 2001). Selected molecular signatures of ovarian cancer
will be discussed as follows.
1.5.1 BRCA1 and BRCA2
In spite of original thoughts suggesting an involvement of BRCA genes only in the
tumorigenesis of inherited ovarian tumours, accumulating evidence points to a role of
BRCA genes in sporadic ovarian cancers. For instance, it has been demonstrated in a
population-based study that promoter hypermethylation of BRCA1 may serve as an
alternative to mutation in causing the inactivation of BRCA1 in sporadic ovarian
cancer (Baldwin et al., 2000). Mutations in BRCA1 and BRCA2 have also been
implicated to be involved in the tumorigenesis of sporadic ovarian cancers via distinct
molecular pathways (Jazaeri et al., 2002). Furthermore, Khoo et al reported somatic
mutations of BRCA1 can be observed in sporadic ovarian tumours implying a tumour
suppressor function of BRCA1 in sporadic cancers (Khoo et al., 1999).
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1.5.2 TP53
TP53 encodes the tumour suppressor protein p53 which is crucial for protection
against neoplasia by inducing apoptotic cell death, DNA damage repair and cell cycle
arrest (Levine et al., 1991). Given the pivotal role of p53 in safeguarding the cell
against a wide range of stresses, it comes with no surprise that mutations of TP53
have been implicated in the malignant progression of multiple types of cancers
including tumours of the ovary (Kupryjanczyk et al., 1993).
1.5.3 PTEN and PI3K
The phosphatase and tensin homolog (PTEN) gene is a tumour suppressor that
dephosphorylates phosphatidylinositol 3,4,5-triphosphate (PIP3) and inhibits the
phosphatidylinositol 3-kinase (PI3K) signaling pathway (Maehama et al., 2001).
Mutations of PTEN resulting in constitutively active PI3K signaling could lead to
enhanced cell proliferation and resistance to apoptosis which are prerequisites of
oncogenic transformation (Manning & Cantley, 2007). Frequent somatic PTEN
mutations have been detected in endometrioid ovarian carcinoma, indicating a role of
PTEN in the development of endometrioid subtype of ovarian cancer (Obata et al.,
1998). Mutations in the p110 subunit of PI3K, namely PI3KCA, have also been
reported to contribute to activation of the PI3K signaling pathway and such mutations
are detected in 12% of ovarian cancers (Levine et al., 2005).
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1.5.4 KRAS and BRAF
KRAS belongs to a family that regulates cell growth, survival and differentiation
through activation of downstream effector pathways including PI3K and RAF
(Schubbert et al., 2007). Mutations in KRAS or BRAF genes are common in low-grade
serous carcinomas and serous borderline ovarian tumours, but are rarely observed in
high-grade ovarian tumours (Wong et al., 2010).
1.5.5 Hox
The HOX family of homeobox genes, originally widely investigated in Drosophila
and is responsible for the modulation of normal axial and spatial development, has
been implicated in lineage differentiation of epithelial ovarian cancer (Rosen et al.,
2009). Cheng et al reported that the HOX genes are not expressed in normal ovarian
surface epithelium, but indeed are observed in different histologic subtypes of
epithelial ovarian cancer (Cheng et al., 2005). It was further demonstrated that ectopic
expression of different members of HOX genes could give rise to tumours resembling
serous, endometrioid and mucinous subtypes of epithelial ovarian cancer, implying a
pivotal role of HOX members in specifying regional identity in the reproductive tract
(Cheng et al., 2005).
1.5.6 c-Myc
The proto-oncogene c-Myc encodes phosphoproteins that play important roles in the
regulation of a wide range of biological processes including cell proliferation,
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apoptosis and differentiation. Although c-Myc overexpression has been documented in
epithelial ovarian cancers, further elaborative studies are necessary to elucidate
whether c-Myc participates in the tumorigenesis of ovarian carcinoma (Chen et al.,
2005; Obaya et al., 1999).
1.5.7 TrkB
Tropomyosin-related kinase B (TrkB) mediates multiple functions in the development
of nervous system including neuronal differentiation and survival. Recently, TrkB
overexpression has been documented in several human cancers (Lewin & Barde,
1996). Intriguingly, TrkB and its ligand, brain-derived neurotrophic factor (BDNF),
have been reported to contribute to ovarian carcinogenesis and may serve as potential
prognostic and therapeutic target of ovarian cancer (Au et al., 2009).
1.6 Models of ovarian carcinogenesis
1.6.1 Hypotheses on ovarian tumorigenesis
Several hypotheses have been proposed to explain the mechanism of ovarian
carcinogenesis. First proposed by Fathalla in 1971, the long-standing incessant
ovulation hypothesis argues that repeated cycles of ovulation-induced trauma and the
subsequent repair of ovarian surface epithelial cells at the site of ovulation contribute
to the development of ovarian cancer (Fathalla, 1971; Risch, 1998). According to this
hypothesis, recurrent rupture, repair and proliferation of ovarian surface epithelial
cells at the ovulation site may accumulate and propagate genomic instability, which
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predisposes this cell layer to tumorigenesis (Ho, 2003). Findings based on
experimental evidence provided support to this hypothesis. For instance, oxidative
DNA damage, expression of p53 and apoptosis occur among the epithelial cells
located within the formative sites of ovulation (Murdoch et al., 2001). La Vecchia et
al further reported a reduced risk of ovarian cancer among women who use oral
contraceptives to suppress ovulation (La Vecchia et al., 1987). In 2007, Piek et al
suggested a revision to the hypothesis by proposing that ovulation increases the risk
of ovarian cancer by elevating the risk of inclusion of exfoliated tubal epithelial cells
into the ovarian stroma and the subsequent enhanced mitotic activity within tubal
epithelium (Piek et al., 2007).
The pituitory/gonadotropin hypothesis suggests that under normal circumstances, the
ovarian epithelium invaginates and forms inclusion cysts and clefts. Overstimulation
by gonadotropins may trigger a cascade of events resulting in the entrapment of
ovarian surface epithelium within the ovarian stroma and the subsequent malignant
transformation (Cramer & Welch, 1983). However, recent experimental findings
failed to support any link between hormone replacement theory and ovarian cancer
(Rodriguez et al., 2001), suggesting an inadequacy of this hypothesis alone to account
for the process of ovarian carcinogenesis.
Alternative hypotheses have been proposed including the androgen/progesterone
hypothesis which suggests an increased risk of ovarian cancer may result from
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elevated levels of androgens produced by the ovarian thecal cells (Risch, 1998).
Similar to the gonadotropin hypothesis, this hypothesis lacks extensive experimental
support.
1.6.2 Dualistic model of ovarian carcinogenesis
Based on a review of clinicopathological and molecular studies, a dualistic model has
been proposed to account for ovarian tumour progression. Briefly, ovarian cancer
could be divided into two groups, namely type I and type II that correspond to two
main pathways of tumorigenesis (Shih Ie & Kurman, 2004). Type I tumours are
low-grade neoplasms which develop in a stepwise manner from well established
precursor lesions called borderline tumours to invasive tumours (Shih Ie & Kurman,
2004; Singer et al., 2005). In addition to low-grade serous carcinomas, type I tumours
are composed of mucinous, endometrioid and clear cell carcinomas. Type I tumours
are genetically stable and characterized by mutations in an array of genes such as
KRAS, BRAF, PTEN and β-catenin (Shih Ie & Kurman, 2004; Singer et al., 2005). In
contrast, type II tumours include high-grade serous carcinoma, malignant mixed
mesodermal tumours and undifferentiated carcinoma and are characterized by de novo
development from in situ changes originated from ovarian surface epithelium or
inclusion cysts (Shih Ie & Kurman, 2004). Unlike type I tumours, type II tumours
tend to be highly genetically unstable and harbour frequent mutations of TP53 (Shih
Ie & Kurman, 2004).
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1.6.3 Epithelial to mesenchymal transition
Epithelial to mesenchymal transition (EMT) is a process by which epithelial cells lose
cell-cell adhesion and gain migratory and invasive properties necessary to become
mesenchymal cells. EMT is crucial for numerous developmental processes and
accumulating findings suggest EMT participates in the initiation of cancer metastasis
(Thiery, 2003). Recently, Ahmed et al described a model based on the development of
EMT to elucidate the progression of ovarian cancer (Ahmed et al., 2007). According
to this model, EMT is crucial for enhanced motility of epithelial ovarian cancer cells.
Rupture of ovarian tumours leads to shedding of cancer cells into the surrounding
peritoneum. Cytokines and growth factors secreted by the tumour microenvironment
are indispensable for facilitating the invasiveness of cancer cells until reaching a
secondary site of attachment (Ahmed et al., 2007). On the other hand, mesenchymal
to epithelial transition (MET) is required for tumour growth on the omentum (Ahmed
et al., 2007).
1.7 Conventional treatments of ovarian cancer
Optimal debulking surgery remains the major treatment for stage I ovarian cancer
which involves total abdominal hysterectomy and bilateral salpingo-oophorectomy
with careful surgical staging. Lymphadenectomy is also considered an important
diagnostic and therapeutic procedure (Colombo et al., 2003). However, given the
non-specific symptoms of ovarian cancer and the lack of effective screening tests,
majority of patients are diagnosed at an advanced stage. Treatment for advanced
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ovarian cancer focuses on cytoreductive surgery and chemotherapy. Radiotherapy is
mainly used as a palliative treatment to alleviate pain. The combination of carboplatin
and paclitaxel has represented the first-line standard treatment.
Unfortunately, the effectiveness of chemotherapy is limited by drug resistance.
Resistance to chemotherapeutic agents can be classified into two categories: intrinsic
or acquired. For patients with intrinsic resistance, they tend to display resistance
before receiving chemotherapy since the tumour cells already harbour
resistance-mediating factors (Holohan et al., 2013). On the other hand, acquired drug
resistance can develop during treatment of tumours that were initially sensitive. This
may be attributable to various mechanisms including mutations arising during
treatment (Holohan et al., 2013). The mode of action and mechanisms of resistance of
several commonly adopted chemotherapeutic drugs will be discussed.
1.7.1 Paclitaxel
Paclitaxel, a member of taxanes, was first isolated in 1971 as the active ingredient of
the crude bark extract of the Pacific yew, Taxus brevifolia (Wani et al., 1971).
Although paclitaxel showed anti-tumour activity shortly after its discovery, it was not
until the mid-1980s that the impressive tumour suppressing activity of paclitaxel in
human tumour xenografts in nude mice had been appreciated and applied to clinical
trials (Oberlies & Kroll, 2004).
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The chemical name of paclitaxel is 5β, 20-epoxy-1, 2α, 4, 7β, 10β,
13α-hexahydroxytax-11-en-9-one4, 10-diacetate2-benzoate 13 ester with (2R,
3S)-N-benzoyl-3-phenyliseseine. The chemical formula is C47H51O14with a molecular
weight of 853.9 (Kumar et al., 2010). The principal mechanism of action involves
disruption of microtubule dynamics.
Microtubules play a pivotal role in a broad spectrum of biological processes including
the initiation of DNA synthesis, mitosis, meiosis, motility as well as intracellular
trafficking of macromolecules and organelles. Paclitaxel acts by binding selectively
and reversibly to the B subunit of tubulin, thus promoting tubulin polymerization and
the formation of stable microtubules (Kumar et al., 2010). Exposed cells generally
exhibit an accumulation of arrays of disorganized microtubules which eventually lead
to profound cell cycle arrest at the G2/M phase and the subsequent apoptotic cell
death (Downing, 2000). It has been demonstrated that paclitaxel-induced apoptosis
and drug resistance is mediated at molecular level by altering the functions of p53,
p21, Bcl-2 and Bcl-xL (Giannakakou et al., 2000; Schmidt et al., 2000). Although
approximately two-thirds of ovarian cancer patients respond to the combinatorial
chemotherapy involving taxanes and platinum compounds, the majority of them will
have disease recurrence due in large to the acquisition of drug resistance (Kumar et al.,
2010).
Several mechanisms have been proposed to explain resistance to paclitaxel. It has
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been suggested elevated expression of the efflux transporter Pgp, multidrug
resistance-associated protein 2, and reduced expression of the influx transporter, such
as the organic anion transporting polypeptide 1 B3 (OATP1B3/SLCO1B3) may
account for the development of chemoresistance (Walle et al., 1995). Other plausible
mechanisms include overexpression of the paclitaxel-metabolizing enzyme CYP2C8,
mutations in tubulin that alter binding capacity of paclitaxel as well as changes in
signaling pathways associated with microtubule function (Bolis et al., 2004; Kumar et
al., 2010; Walle et al., 1995). Given the efficacy of paclitaxel as front-line
chemotherapeutic agent for ovarian cancer, it is of utmost importance to elucidate
detailed mechanisms underlying the acquisition of drug resistance while exploring
novel agents.
1.7.2 Cisplatin
cis-diamminedichloroplatinum (II) (commonly known as cisplatin or CDDP) was first
adopted for the treatment of testicular and bladder cancer in 1978. It has now become
a widely employed platinum-based therapeutic compound for a broad spectrum of
solid neoplasms including ovarian, colorectal and lung cancers (Galanski, 2006).
Given the cytotoxicity of cisplatin affecting kidneys and peripheral nerves,
cis-diammine (cyclobutane-1, 1-dicarboxylate-O, O') platinum (II) (carboplatin) was
later developed as a second-generation platinum compound that functions similarly to
cisplatin yet possesses reduced side effects (Harrap, 1985).
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The most prominent mode of action of cisplatin involves the generation of DNA
lesions followed by the activation of DNA damage response and apoptotic cell death
(Galluzzi et al., 2012). The major signaling pathway leading to apoptosis is the
sequential activation of ataxia telangiectasia mutated (ATM)- and RAD3-related
protein (ATR) and checkpoint kinase I (CHEK1) which in turn phosphorylates the
tumour suppressing TP53 triggering apoptosis (Galluzzi et al., 2012). Unlike most
patients of lung, prostate and colorectal cancers that demonstrate intrinsic resistance
to cisplatin-based therapies, acquired chemoresistance is frequently observed in
ovarian cancer patients (Koberle et al., 2010).
Resistance to cisplatin often presents a multifactorial nature. For example,
down-regulation of copper transporter 1 (CTR1) has been documented in
cisplatin-resistant cancer cell lines which might result in reduced cisplatin uptake
(Ishida et al., 2002). Overexpression of multidrug resistant protein 2 (MRP2) has also
been shown to account for an increased efflux of cisplatin in resistant cells (Liedert et
al., 2003). Furthermore, mutations or down-regulations of MLH1 and MSH2, which
constitute part of the mismatch repair system, have also been implicated in the context
of acquired cisplatin resistance (Aebi et al., 1996; Gifford et al., 2004).
1.7.3 Tamoxifen
The anti-oestrogen tamoxifen is the most commonly used treatment for patients with
oestrogen-receptor alpha (ER)-positive breast cancer. Although there has been some
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evidence from observational studies suggesting that tamoxifen may generate a
response in women with relapsed ovarian cancer, no conclusive findings from
randomized controlled trials are available (Williams, 2001).
1.8 Survival and prognosis
As mentioned in previous sections, only approximately 25% of ovarian cancers are
diagnosed at an early stage (I and II FIGO stages), while for 70% of cases the
diagnosis is poised at late stages. The five-year survival of these patients is 70-90% in
stage I, 50-60% in stage II, 20-40% in stage III and 10% in stage IV (Rescigno et al.,
2013). Tumour cell type was further reported to be the most relevant histopathological
prognostic factor in patients treated with surgery and chemotherapy. Mucinous and
clear cell carcinomas are considered highly lethal (Alexandre et al., 2010; Zaino et al.,
2011).
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1.9 Scope of Study
Hypothesis
FOXM1 is dysregulated in ovarian cancer and contributes to tumorigenesis and
acquisition of paclitaxel resistance
Objectives
-To characterize the expression pattern of FOXM1 in ovarian cancer patient samples
and determine potential correlation with clinicopathological parameters
-To study the roles of FOXM1 in ovarian cancer metastasis and acquisition of
paclitaxel resistance
-To identify novel FOXM1 transcriptional targets that might be implicated in
chemoresistance
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Chapter 2
Forkhead box protein M1 (FOXM1) expression and
clinicopathological parameters in ovarian cancer
2.1 Introduction
2.1.1 Forkhead box (FOX) proteins
Forkhead box (FOX) proteins constitute an extensive family of transcriptional
regulators that are characterized by an evolutionarily conserved "forkhead" or
"winged-helix" DNA-binding domain (DBD) (Myatt & Lam, 2007). With the first
member being identified more than two decades ago, fifty FOX proteins have so far
been identified and they are categorized into 19 subgroups (FOXA to FOXS)
according to sequence homology (Kaestner et al., 2000). The FOX superfamily of
proteins are multifunctional transcription factors responsible for the spatio-temporal
fine tuning of a broad repertoire of transcriptional programs that are involved in cell
cycle progression, proliferation, differentiation, metabolism, senescence, survival and
apoptosis (Myatt & Lam, 2007). In addition to serving as transcription activators and
repressors, FOX proteins also act as pioneer factors capable of unwinding compacted
chromatin rendering it accessible to other factors to bind (Lam et al., 2013). Given the
utmost importance of FOX proteins, it comes with no surprise that deregulation of
their modes of transcriptional regulation and action will lead to pathological
conditions including cancer. Key members of five subfamilies, FOXA, FOXC, FOXP,
FOXO and FOXM1 will be discussed below with an emphasis on their emerging roles
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in carcinogenesis.
2.1.2 FOXA
FOXA family members include FOXA1, FOXA2 and FOXA3. FOXA proteins are
characterized by an N-terminal transactivation domain (TAD), followed by forkhead
DNA-binding domain (FHD) and a C-terminal TAD (Lam et al., 2013) (Figure 2.1).
FOXA1 and FOXA2 have been demonstrated to be necessary in concert for hepatic
specification in mice, suggesting a role in liver development (Lee et al., 2005).
FOXA2 is also required for normal bile acid homeostasis as the liver samples of
individuals with different cholestatic syndromes harbour markedly reduced FOXA2
expression (Bochkis et al., 2008). A recent study reported FOXA3 regulates adipocyte
differentiation and depot-selective fat tissue expansion (Xu et al., 2013). FOXA1 is
also capable of regulating steroid hormone signaling as a pioneer factor by inducing
chromatin modifications and the subsequent recruitment of other transcription factors
(Gao et al., 2003; Lupien et al., 2008).
Intriguingly, FOXA1 and FOXA2 play differential roles in males and females during
hepatocarcinogenesis in that they cooperate with estrogen receptor (ERα) to suppress
and androgen receptor (AR) to promote liver cancer in females and males respectively
(Z. Li et al., 2012). The seemingly paradoxical role of FOXA proteins to serve as both
oncoproteins and tumour suppressors has also been documented in other cancer types.
For example, although amplification and overexpression of FOXA1 has been reported
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in cancers of lung, prostate, breast and oesophagus (Cancer Genome Atlas Network,
2012; Lin et al., 2002; Robbins et al., 2011), loss of FOXA1 is associated with high
grade, late stage bladder cancer and enhanced tumour proliferation (DeGraff et al.,
2012).
Figure 2.1. Schematic diagram depicting structural organization of FOXA1,
FOXC1, FOXP3, FOXO3A and FOXM1 which are typical members of the five
subfamilies. FHD: Forkhead binding domain; ID: Inhibitory domain; LZ:
Leucine zipper; NES: Nuclear export signal; NLS: Nuclear localization signal;
NRD: N-terminal repressor domain; TAD: Transactivation domain; TRD:
Transcriptional repressor domain. Modified from (Lam et al., 2013).
NRD FHD TADFOXM1
FOXO3A NLSFHD TADNES
FOXA1 TAD FHD TADTAD
IDTAD FHD/NLS TADFOXC1
NLSFHDTRD LZFOXP3
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2.1.3 FOXC
FOXC family includes FOXC1 and FOXC2 that contain an N-terminal transactivation
domain, forkhead binding domain followed by inhibitory domain and a C-terminal
transactivation domain (Figure 2.1). FOXC1 and FOXC2 play interactive pivotal roles
in the early processes of heart development by acting upstream of the Tbx1-FGF
signaling cascade during the morphogenesis of the outflow tract (Seo & Kume, 2006).
FOXC1 is also expressed by brain pericytes during development and is crucial for
pericyte regulation of vascular development in the fetal brain (Siegenthaler et al.,
2013). Overexpression of FOXC2 has been shown to stimulate osteogenic
differentiation and inhibit aipogenic differentiation in bone marrow mesenchymal
stem cells (You et al., 2014).
FOXC proteins are also implicated in promoting EMT and carcinogenesis. EMT is a
key developmental program that is often activated during cancer invasion and
metastasis. Mani et al reported the involvement of FOXC members in EMT and
maintenance of stem cell properties, suggesting FOXC proteins participate in the
development of cancer (Mani et al., 2008). This is consistent with a recent finding
establishing FOXC2 expression as a link between EMT and stem cell properties in
breast cancer (Hollier et al., 2013). FOXC1 expression predicts poor survival of
breast cancer patients and may serve as a potential molecular therapeutic target in
basal-like breast cancer (Ray et al., 2010). Elevated expression of FOXC1 has been
demonstrated to be associated with poor clinical outcome for non-small cell lung
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cancer patients and pancreatic ductal adenocarcinoma patients (Wang et al., 2013;
Wei et al., 2013). FOXC2 has recently been shown to be critical for
resveratrol-mediated suppression of lung cancer progression (Yu et al., 2013).
2.1.4 FOXP
FOXP proteins consist of FOXP1, FOXP2, FOXP3 and FOXP4. FOXP proteins are
characterized by transcription repressor domain, leucine zipper followed by forkhead
binding domain and nuclear localization signal (Figure 2.1). Similar to FOXA
proteins, FOXP proteins have also been shown to possess both oncogenic and tumour
suppressing properties. For example, although elevated expression of FOXP1 is
associated with improved survival in patients with non-small cell lung cancer (Feng et
al., 2012), down-regulation of FOXP1 has been reported in endometrial and prostate
cancer (Giatromanolaki et al., 2006; Takayama et al., 2008).
Mutations in FOXP2 are the only known cause of developmental speech and language
disorders in humans. Using chromatin immunoprecipitation coupled with microarray
analysis, Spiteri et al provided the first insight into the functional network of genes
directly regulated by FOXP2 in human brain (Spiteri et al., 2007). The presence of
leuzine zippers enables FOXP2 to heterodimerize and cooperate with FOXP1 in the
modulation of lung and oesophageal development (Shu et al., 2007). Elevated FOXP2
mRNA and protein expressions have been detected in lymphoma and multiple
myeloma-derived cell lines (Campbell et al., 2010). Recently, overexpression of
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FOXP2 has been associated with advanced tumour stage and lymph node metastasis
only in ERG fusion-negative prostate cancer, but not in the ERG fusion-positive
cancer, implicating the paradoxical role of FOXP2 (Stumm et al., 2013).
FOXP3 has long been established to play a pivotal role in the normal functioning of
CD4+CD25+ regulatory T (Treg) cells and mutations in FOXP3 are associated with
inherited autoimmune diseases (Ouyang et al., 2010). FOXP3 also participates in
normal reproductive function and it has been reported FOXP3 mutant mice harbour
significantly reduced expression of pituitary gonadotropins (Jasurda et al., 2013). Zuo
et al reported in a recent intriguing study that FOXP3 serves as an X-linked breast
cancer suppressor gene (Zuo et al., 2007a). The authors further established FOXP3 as
a novel transcriptional repressor for the breast cancer oncogene SKP2 (Zuo et al.,
2007b). Subsequent investigations revealed up-regulation of FOXP3 is capable of
inhibiting cell proliferation, migration and invasion of epithelial ovarian cancer cells
(Zhang & Sun, 2010).
FOXP4 is necessary for normal T cell cytokine recall responses to antigen following
pathogenic infection (Wiehagen et al., 2012). FOXP4 and FOXP2 are also
progressively expressed  upon neural differentiation in the spinal cord thus essential
for the regulation of neuroepithelial character as well as progenitor maintenance in the
central nervous system (Rousso et al., 2012). Dysregulation of FOXP4 has been
documented in various cancer types including prostate cancer (Takata et al., 2010).
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2.1.5 FOXO
FOXO family members include FOXO1 (FKHR), FOXO3A (FKHRL1), FOXO4
(AFX) and FOXO6. FOXO proteins contain the forkhead binding domain, nuclear
localization signal, followed by nuclear export signal and a C-terminal transactivation
domain (Figure 2.1). FOXO transcription factors are responsible for the regulation of
a broad spectrum of biological functions, including cell proliferation, apoptosis,
differentiation and metabolism. Dysregulations of FOXOs have been implicated in
multiple bodily disorders such as diabetes mellitus, neurodegeneration and cancer
(Monsalve & Olmos, 2011).
FOXO1 plays a critical role in normal vascular development by enabling endothelial
cells to respond properly to a high dose of vascular endothelial growth factor (VEGF)
(Furuyama et al., 2004). FOXO1 also cooperates with other transcription factors in
the regulation of hepatic gluconeogenesis (Oh et al., 2013). FOXO4 has been shown
to be necessary for neural differentiation of human embryonic stem cells (Vilchez et
al., 2013). In addition to promoting memory consolidation by regulating a program
coordinating neuronal connectivity in the hippocampus (Salih et al., 2012), FOXO6 is
also an important regulator of hepatic glucose metabolism in response to insulin or
physiological cues (Kim et al., 2013). Not surprisingly, FOXO1, FOXO4 and FOXO6
have all been involved in the development of cancer. For example, the anti-apoptotic
function of miR-96 in prostate cancer is mediated by inhibiting FOXO1 (Fendler et al.,
2013). FOXO1 is also able to mediate cisplatin resistance in gastric cancer cells by
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activating the PI3K/Akt pathway (Park et al., 2013). FOXO4 has been documented to
mediate the oncogenic functions of miR-421 in human nasopharyngeal carcinoma
(Chen et al., 2013). Although FOXO6 has garnered relatively less attention as
compared to other FOXO members, recent evidence suggests an oncogenic role of
FOXO6 in promoting gastric cancer cell tumorigenicity through up-regulation of
c-Myc (Qinyu et al., 2013).
FOXO3A is an important member of the FOXO family of transcription factors. It is
an established bona fide tumour suppressor involved in a variety of anti-tumour
functions such as cell cycle arrest, DNA damage repair and apoptotic cell death. In
particular, p27Kip1, Gadd45α and Bim are direct gene targets of FOXO3A involved in
these processes. It has been documented that FOXO3A is a regulator of ERα and its
overexpression results in a reduction of ER-mediated tumour growth in ER-positive
breast cancers (Zou et al., 2008). However, emerging evidence has uncovered a flip
side of FOXO3A (Lam et al., 2012). Persistent activation of FOXO3A by doxorubicin
in multi-drug resistant leukemia cells is capable of promoting survival and drug
resistance through the hyperactivation of PI3K/Akt signaling pathway (Hui et al.,
2008). Previous finding on the exclusive nuclear accumulation of FOXO3A in
doxorubicin resistant breast cancer cells is supported by a recent study in thyroid
cancer thereby providing further evidence on the uncoupling of FOXO3A from the
PKB/Akt signaling cascade (Chen et al., 2010; Marlow et al., 2012).
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2.1.6 FOXM1
FOXM1 is one of the best characterized member of the FOX proteins and contains an
N-terminal repressor domain, forkhead binding domain and a C-terminal
transactivation domain (Figure 2.1). While the FOXO family of transcription factors
behave as tumour suppressors, FOXM1 functions like a classic oncogene. FOXM1 is
critical to a broad spectrum of biological functions including cell differentiation,
apoptosis, angiogenesis, senescence, tissue homeostasis, cell cycle progression and
DNA damage repair (Myatt & Lam, 2007). Overexpression of FOXM1 has been
implicated in cancers of the liver, prostate, breast, lung and colon etc. (Myatt & Lam,
2007; Pilarsky et al., 2004). Several independent gene expression profiling studies
have consistently identified FOXM1 as one of the most commonly up-regulated genes
in human solid tumours (Okabe et al., 2001; Pilarsky et al., 2004; Uddin et al., 2011),
suggesting a pivotal role of FOXM1 in carcinogenesis. Consistent with this notion,
FOXM1 is capable of inducing the expansion of stem cell compartments, leading to
the initiation of hyperplasia during tumorigenesis (Zhao & Lam, 2012).
In addition to initiating the development of cancer, FOXM1 also plays a central role
in cancer progression by promoting the acquisition of stem cell (SC) and EMT
phenotypes. Accordingly, FOXM1 enhances EMT and SC compartment expansion
through activating the expression of mesenchymal/stem cell markers such as Snail2,
E-cadherin and vimentin which eventually give rise to enhanced cell proliferation,
self-renewal, cell migration, angiogenesis as well as drug resistance (Bao et al., 2011).
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Furthermore, it has been demonstrated FOXM1-deficient cells generally display
polyploidy, aneuploidy and chromosome missegregation and an increase in the
number of DNA breaks, highlighting FOXM1 in the maintenance of genomic integrity
(Laoukili et al., 2005; Laoukili et al., 2007).
Accumulating evidence suggests FOXM1 serves a crucial role in drug responsiveness
and resistance (Chen et al., 2010; Francis et al., 2009; Myatt & Lam, 2007). For
instance, deregulated FOXM1 expression contributes to resistance of
chemotherapeutic agents, such as cisplatin and epirubicin, and safeguards cells against
DNA-damage induced cell death (Francis et al., 2009; Kwok et al., 2010; Millour et
al., 2011). The checkpoint kinases Chk1 and Chk2 phosphorylate and activate
FOXM1 upon DNA damage, which in turn induces the expression of genes crucial for
homologous recombination such as BRCA2, XRCC1 and PLK4 (Park et al., 2012;
Tan et al., 2007). As a consequence, cancer cells with deregulated FOXM1 expression
become more proficient in DNA-damage repair, resulting in resistance to genotoxic
therapeutics. FOXM1 also participates in the acquisition of endocrine resistance in
breast cancer (Millour et al., 2010). This is attributable to the fact that FOXM1 is
subjected to transcriptional regulation of ERα, and that FOXM1 also regulates ERα
expression in breast cancer cells (Madureira et al., 2006). The mutual regulation
culminates in a positive forward feeding loop that contributes to tumorigenesis and
hormone-insensitivity in endocrine-related malignancies (Madureira et al., 2006).
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2.1.7 FOXO-FOXM1 axis in tumorigenesis and drug resistance
Intriguingly, FOXM1 and FOXO3A possess antagonistic functions in the regulation
of target genes in that genes activated by FOXM1 are often suppressed by FOXO3A
(Koo et al., 2012). FOXM1 is a direct transcriptional target inhibited by FOXO
proteins and a pivotal effector of the PI3K-AKT-FOXO signaling axis in the
mediation of multiple biological processes including cell migration and differentiation
(Francis et al., 2009; McGovern et al., 2009; Wilson et al., 2011) (Figure 2.2). FOXO
and FOXM1 are also indirect targets of several widely adopted chemotherapeutic
agents. For example, cytotoxic drugs such as doxorubicin and cisplatin function partly
by targeting the PI3K-AKT-FOXO-FOXM1 axis (Lam et al., 2013) (Figure 2.2).
Given the vital roles of FOXO and FOXM1 in the normal functioning of anti-cancer
drugs, it is not surprising that deregulation of this functional axis results in the
acquisition of drug resistance.
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Figure 2.2. Targeting the FOXO-FOXM1 axis in cancer therapeutics.
Chemotherapeutic drugs have various modes of action but ultimately integrate signals
with the PI3K-AKT-FOXO-FOXM1 signaling cascade. FOXO and FOXM1 then
exert antagonistic functions in the regulation of target genes, which in turn control
cancer-related processes including drug resistance, angiogenesis and migration.
Modified from (Zhao & Lam, 2012).
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2.1.8 Aim:
1. To characterize the expression profile of FOXM1 in ovarian cancer tissue samples
2. To determine if FOXM1 expression correlates with clinicopathological parameters
3. To study if FOXM1 affects migration and invasion of ovarian cancer cells
4. To elucidate the role of FOXM1 in the acquisition of paclitaxel resistance in
ovarian cancer
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2.2 Materials and methods
2.2.1 Clinical samples and cell lines
Archival paraffin embedded tissue blocks from year 1987 to 2002 were retrieved from
the Department of Pathology, Queen Mary Hospital, the University of Hong Kong.
The samples included 2 benign cystadenomas, 2 borderline tumours, 94 primary
carcinomas and 21 metastatic foci of cancer (at ligament, gut, lymph node and uterine
serosa). All patients underwent surgery followed by the standard first-line
chemotherapy including platinum/paclitaxel. The follow-up period ranged from 5 to
209 months (median 63 months). The use of these samples was approved by the
Institutional Ethical Review Board. Each patient sample was assessed by pathologists
and ensured to contain more than 70% tumour cells.
Ovarian cancer cell lines SKOV-3 and OVCAR-3 were purchased from American
Type Culture Collection (Manassas, VA, USA). SKOV3-TR cells were a generous
gift from Dr Lawrence XF Le (Division of Cancer Medicine, University of Texas
M.D. Anderson Cancer Center, Houston, Texas, USA) (Siu, et al., 2010a). OVCAR-3
was cultured in 1:1 Medium 199 (Invitrogen, CA, USA): MCDB105 (Sigma, MO,
USA) supplemented with 10% foetal bovine serum (FBS) and 100 units/ml
penicillin-streptomycin (Invitrogen). SKOV-3 and SKOV3-TR were cultured in
RPMI1640 (Sigma) supplemented with 10% foetal bovine serum (FBS) and 100
units/ml penicillin-streptomycin (Invitrogen). All cell lines were maintained at 37°C
in humidified incubator with 5% CO2. Cell culture medium was changed every 3 to 5
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days depending on cell density. For routine passage, when cells reached 85% to 90%
confluency, they were split at a ratio of 1:4.
2.2.2 Immunohistochemistry
Immunohistochemistry was performed as described previously (F. Zhao et al., 2011).
Briefly, formalin-fixed paraffin sections were stained with anti-FOXM1 antibody
(NBP1-30961, 1:40, Novus Biologicals, CO, USA) using EnVision+ Dual Link
System (K4061; Dako, CA, USA). Antigen retrieval was performed using EDTA
buffer, pH8.0, in a pressure cooker for 30 min. Benign cystadenomas with no FOXM1
expression were included as negative tissue control. All sections were assessed by two
independent investigators. The immunoreactivity of FOXM1 antibody, the intensity
of stained cells and their percentages were measured in terms of intensity and
percentage scores respectively. The percentage score ranged from 0 to 4: 0 = <5% of
positively stained cells, 1 = 5-25% of positively stained cells, 2 = 26-60% of
positively stained cells, 3 = 61-85% of positively stained cells, and 4 = 86-100% of
positively stained cells. Immunohistochemical (IHC) score (from 0 to 16) was
calculated by multiplying the intensity score (0-4) and the percentage score (0-4),
with a maximum score of 16 (Siu et al., 2010a; F. Zhao et al., 2011). FOXM1 nuclear
and cytoplasmic immunoreactivities were scored separately.
2.2.3 Western blot
Cells were harvested with lysis buffer [0.125 m Tris, pH 6.8 at 22°C containing 1%
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NP-40 (v/v), 2 mM ethylenediamine tetraacetic acid (EDTA), 2 mM
N-ethylmaleimide, 2 mM phenylmethanesulphonyl fluoride (PMSF), 1 mM sodium
orthovanadate and 0.1 μm sodium okadate] and centrifuged at 4°C for 10 min. Protein
concentration was determined by detergent-compatible (DC) protein assay (Bio-Rad).
Twenty micrograms of protein were separated by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to
polyvinylidene difluoride membrane and hybridized with the following anti-bodies:
anti-FOXM1 (sc-502, Santa Cruz Biotechnology, CA, USA), anti-Caspase 9 (9502,
Cell Signaling Technology, MA, USA), anti-Caspase 7 (9492, Cell Signaling) and
anti-β-tubulin (sc-9104, Santa Cruz Biotechnology).
2.2.4 Transient knockdown of FOXM1
ON-TARGET Plus Human FOXM1 siRNA and Non-targeting Control siRNAs
(Thermo Scientific, CO, USA) were employed for transient silencing of FOXM1
using Oligofectamine transfection reagent (Invitrogen). Briefly, for each well of a
6-well plate of cells at 80-90% confluency, two reaction mixes were prepared. Mix 1
contains 60μl of Opti-MEM Reduced Serum Medium (Gibco) and 5μl of
Oligofectamine transfection reagent, whereas mix 2 contains 250μl of Opti-MEM
Reduced Serum Medium, 7.5μl of 1X siRNA buffer (Dharmacon) and 7.5μl of 20μM
non-targeting control or FOXM1 siRNA. Mix 2 was added to mix 1 and the resulting
mixture was left at RT for 25 min, before being diluted with 170μl of Opti-MEM
Reduced Serum Medium. 500μl of the reaction mixture was then added to each well
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and 2ml of RPMI1640 medium was added after an incubation of 4 h.
2.2.5 In Vitro migration and invasion assays
In Vitro migration and invasion assays were performed as described previously (Liao
et al., 2009). Briefly, 1.25x105 cells were plated on the upper compartment of a
Transwell chamber (Corning Life Sciences, MA, USA). For migration assays, cells
were allowed to migrate through a gelatin-coated membrane. For invasion assays,
cells were allowed to invade through a matrigel-coated membrane. After 24 h, cells on
the upper side of the membrane were removed and the migrated or invaded cells were
fixed, stained and counted.
2.2.6 TdT-mediated dUTP nick end labeling (TUNEL) assay and evaluation of
mitotic catastrophe index
Following FOXM1 knockdown for 48h and paclitaxel treatment (50nM) for 24h,
TUNEL assay was performed using In Situ Death Detection Kit (Roche Biochemical,
IN, USA) following the manufacturer's protocol (Liao et al., 2009). Apoptotic and
mitotic catastrophe figures were assessed under fluorescence microscopy. Mitotic
catastrophe figures were observed by morphological changes in nuclei (DAPI staining)
(Jiang et al., 2011). More than 1000 viable cells in each experiment were examined
and the mitotic catastrophe index was evaluated as percentages of the cells counted.
Every assay was run in triplicate.
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2.2.7 Cell cycle analysis
Cell cycle analysis was performed by propidium iodide staining as described
previously (Kwok et al., 2008). Briefly, both adherent and suspension cells were
harvested and stained with propidium iodide (1mg/mL) in the presence of DNase-free
RNase for flow cytometric analysis. Cell cycle profile was analyzed by using the Cell
Diva software (Becton Dickinson UK Ltd.).
2.2.8 Statistical analysis
Statistical analysis was performed by the Statistical Package for Social Science
version 19.0 for Windows (IBM). Comparison between two groups of non-parametric
data was performed by Mann-Whitney U-test. Probability of survival was analyzed
using the Kaplan-Meier approach without stratification to other clinical and
pathological parameters such as stage and grade. Multivariate analysis taking other
parameters into consideration was performed using Cox’s regression model. P-values
of <0.05 were considered to be statistically significant.
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2.3 Results
2.3.1 FOXM1 overexpression correlates with poor survival
The expression of FOXM1 in ovarian benign and borderline tumours as well as
invasive cancers was evaluated by immunohistochemistry. Ovarian cancers displayed
stronger nuclear FOXM1 staining than benign and borderline tumours. However,
there was no significant difference in FOXM1 expression between primary
carcinomas and their metastatic foci. Higher nuclear FOXM1 expression was
significantly associated with advanced stages of ovarian cancer (P=0.035) (Figure 2.3
Upper panel). Although not reaching statistical significance, FOXM1 overexpression
displayed a trend related to serous histological type (P=0.142), high grade cancers
(poor differentiation) (P=0.235) and chemoresistance (P=0.282) (Table 2.1). In order
to study the association of FOXM1 expression with patients' outcome, patients were
categorized into two groups using the cutoff point of IHC score >0. As shown in the
Kaplan-Meier overall survival plot (Figure 2.3 Lower panel), patients with a low
FOXM1 level had a significantly longer overall (P=0.019) and disease-free survival
(P=0.014) than those with high FOXM1 expression. Multivariate progression analysis
showed high expression of FOXM1, advanced cancer stages and poor histological
differentiation (high grade) were found to be independent prognostic factors for short
overall survival (95% CI, 0.906-5.754, P=0.08; 95% CI, 0.953-5.963, P=0.06; 95%
CI, 2.137-40.638, P=0.003, respectively) and disease-free survival (95% CI,
1.025-6.631, P=0.04; 95% CI, 1.039-6.555, P=0.04; 95% CI, 1.821-35.091, P=0.006,
respectively). Interestingly, cytoplasmic staining of FOXM1 was also detected in
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addition to nuclear expression, but no significant correlation with clinicopathological
parameters was observed.
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Figure 2.3. Elevated nuclear FOXM1 expression was associated with advanced
stages and poor patient survival of ovarian cancer. Upper panel: Representative
images of Immunoreactivity of nuclear FOXM1 in (I) benign cystadenoma (staining
intensity 0, staining percentage 0, IHC score 0), (II) borderline cystadenoma (staining
Higher FOXM1 expression (n=53)
Lower FOXM1 expression (n=29)
Higher FOXM1 expression (n=53)
Lower FOXM1 expression (n=29)
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intensity 2, staining percentage 1, IHC score 2), (III) stage I invasive cancer (staining
intensity 0, staining percentage 0, IHC score 0), (IV) stage II invasive cancer (staining
intensity 4, staining percentage 1, IHC score 4), (V) stage III invasive cancer (staining
intensity 4, staining percentage 2, IHC score 8) and (VI) stage IV invasive cancer
(staining intensity 4, staining percentage 3, IHC score 12). Magnifications X400.
Insets: Regions with higher magnifications of nuclear FOXM1 staining. Lower panel:
Cumulative overall and disease-free survival plots using the Kaplan-Meier approach.
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Table 2.1. Summary of nuclear FOXM1 immunohistochemical staining results in
various types of ovarian tumours.
* p value reflects the comparison of serous ovarian cancer vs. all the other histological types combined
†p value reflects the comparison of stage I vs. stage II-IV
‡p value reflects the comparison of low grade (grade I) vs. high grade (grade II and III)
Nuclear expression of FOXM1
Absent
(IHC=0)
Weak
(IHC=1-3)
Moderate
(IHC=4-6)
Strong
(IHC=7-12)
 Total  p-value
Benign 1 (50%) 1 (50%) 0 (0%) 0 (0%) 2
  Borderline 0 (0%) 2 (100%) 0 (0%) 0 (0%) 2
Invasive cancer 31 (33%) 28 (29.8%) 25 (26.6%) 10 (10.6%) 94Diagnostic
Categories
Metastatic foci 3 (14.3%) 8 (38.1%) 6 (28.6%) 4 (19%)   21
Mucinous 3 (33.3%) 4 (44.4%) 1 (11.1%) 1 (11.1%) 9
Serous 11 (31.4%) 7 (20%) 11 (31.4%) 6 (17.1%) 35 0.142*
Endometrioid 14 (45.2%) 10 (32.3%) 7 (22.6%) 0 (0%) 31Histologica
l
Types
Clear cell 4 (21.1%) 7 (36.8%) 5 (26.3%) 3 (15.8%) 19
  Stage I 15 (41.7%) 11 (30.6%) 9 (25%) 1 (2.78%) 36
Stages
 Stage II-IV 12 (24%) 13 (26%) 16 (32%) 9 (18%) 50 0.035†
  Grade I 10 (41.7%) 8 (33.3%) 5 (20.8%) 1 (4.17%) 24
Grades Grades II-III 22 (31.9%) 19 (27.5%) 19 (27.5%) 9 (13%) 69 0.235‡
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2.3.2 Transient knockdown of FOXM1 inhibits SKOV-3 cell migration and
invasion
We next studied the role of FOXM1 in ovarian cancer progression. In Vitro Transwell
assays were employed to study the effects of transient silencing of FOXM1 on
ovarian cancer cell motility and invasion. Significantly decreased migration and
invasion (P<0.05) was observed in SKOV-3 cells transfected with ON-TARGET Plus
Human FOXM1 siRNA (siFOXM1) as compared to cells transfected with
non-targeting controls, indicating that knockdown of FOXM1 was capable of
inhibiting migration and invasion of SKOV-3 cells (Figure 2.4). No changes in cell
proliferation were observed after FOXM1 knockdown.
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Figure 2.4. Silencing of FOXM1 reduced migration and invasion of SKOV-3. A:
Representative images showing cells migrated (gelatin-coated membrane) or invaded
(matrigel-coated membrane) after 24 h. B. Representative Western blot analysis
demonstrating the effectiveness of FOXM1 transient knock-down in SKOV-3. C.
Graphic representation of migration (left panel) and invasion (right panel) results as
fold change of migrated and invaded cells relative to the control, respectively, in five
fields of triplicate wells from three independent experiments; * P<0.05, significant;
Mann-Whitney U-test.
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2.3.3 Paclitaxel treatment downregulates the expression of FOXM1 in SKOV-3
but not in the paclitaxel-resistant SKOV3-TR
In view of the IHC staining showing that elevated FOXM1 expression is associated
with poor prognosis and thus chemoresistance, a pair of established ovarian cancer
cell line sensitive and resistant to paclitaxel, namely SKOV-3 and SKOV3-TR
respectively, were used to study the effect of paclitaxel treatment on the expression of
FOXM1. Cells were treated with paclitaxel (100nM) (Ofir et al., 2002) and harvested
at various time points 0, 8, 16, 24, 48 and 72 h. Intriguingly, immunoblotting showed
FOXM1 expression to be up-regulated transiently at 8 h and decreased at 48 h and 72
h in SKOV-3. However, FOXM1 expression remained relatively constant at high
levels in SKOV3-TR upon paclitaxel treatment (Figure 2.5), suggesting a role of
FOXM1 in mediating paclitaxel resistance in ovarian cancer cells. Notably, there also
appeared to be only marginal increases in the expression of cleaved Caspase-9 and
Caspase-7 in both SKOV-3 and SKOV3-TR upon paclitaxel treatment (Figure 2.5),
suggesting that apoptosis may not be the predominant mechanism of inducing cell
death in these ovarian carcinoma cells.
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Figure 2.5. Paclitaxel treatment down-regulated FOXM1 expression in SKOV-3
but not in SKOV3-TR cells.
The paclitaxel sensitive SKOV-3 and resistant SKOV3-TR ovarian cancer cells were
treated with 100nM paclitaxel and harvested at times indicated for Western blot
analysis. Paclitaxel treatment down-regulated FOXM1 expression at time points 48h
and 72h in SKOV-3 but not in SKOV3-TR as shown by immunoblotting. There were
only marginal increases in the expression of cleaved Caspase-9 and Caspase-7.
Representative images were shown from three independent experiments. .
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2.3.4 FOXM1 knockdown increases the accumulation of G2/M and dead cells
upon paclitaxel treatment in the resistant SKOV3-TR cell lines.
Cell cycle analysis was then performed to investigate the role of FOXM1 in
paclitaxel-mediated cell death. To this end, SKOV-3 and SKOV3-TR cells were
transiently transfected with control and FOXM1 siRNA for 48 h and cultured in the
presence or absence of paclitaxel treatment (100nM) for 48 h. Cells were then
harvested, stained with propidium iodide and subjected to flow cytometric analysis.
The results showed that paclitaxel induced significant levels of cell death (sub-G1
population) in SKOV-3 cells transfected with either FOXM1 or control siRNA pool
(Figure 2.6). Increased number of cells accumulated with sub-G1 DNA contents in
SKOV3-TR with FOXM1 knockdown (8.1%) (Figure 2.7) compared to SKOV3-TR
transfected with control siRNA (4.2%) (Figure 2.7), suggesting FOXM1 contributes
to paclitaxel resistance in ovarian cancer cells and that FOXM1 silencing can induce
paclitaxel-mediated cell death. Upon paclitaxel treatment, though not reaching
statistical significance, a modest increase in cells blocked at G2/M phase was also
observed in SKOV3-TR treated with siRNA against FOXM1 as compared to control,
suggesting FOXM1 silencing might enhance paclitaxel-mediated cell death via
mitotic catastrophe (Figure 2.7, lower panel). Depletion of FOXM1 in the sensitive
SKOV-3 cells has no additive effect to paclitaxel treatment which is likely to be due
to the fact that paclitaxel functions through downregulating FOXM1 expression as
revealed by the Western blot analysis (Figure 2.5).
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Figure 2.6. Flow cytometric analysis of SKOV-3 cells with and without FOXM1
depletion in the presence or absence of paclitaxel treatment.
Upper panel: Flow cytometric analysis was performed following propidium iodide
staining on SKOV-3 cells treated with paclitaxel (100nM) or remained untreated after
transfection with siRNA pools against FOXM1 or control siRNA pools.
Representative histogram was shown. Lower panel: Bar chart of different phases of
cell cycle in SKOV-3 treated with paclitaxel after transfection with control or siRNA
against FOXM1. Results represent data from two independent experiments.
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Figure 2.7. Flow cytometric analysis of SKOV3-TR cells with and without
FOXM1 depletion in the presence or absence of paclitaxel treatment.
Upper panel: Flow cytometric analysis was performed following propidium iodide
staining on SKOV3-TR cells treated with paclitaxel (100nM) or remained untreated
after transfection with siRNA pools against FOXM1 or control siRNA pools.
FOXM1 silencing is capable of inducing a modest increase in the number of dead
cells in sub-G1 population and cells blocked at G2/M cell cycle phase in SKOV3-TR
as compared to cells treated with control siRNA. Representative histogram was shown.
Lower panel: Bar chart of different phases of cell cycle in SKOV3-TR treated with
paclitaxel after transfection with control or siRNA against FOXM1. Results represent
data from two independent experiments.
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2.3.5 Transient silencing of FOXM1 significantly enhances paclitaxel-mediated
mitotic catastrophe
To elucidate the potential role of FOXM1 in ovarian cancer chemoresistance, the
SKOV-3 and OVCAR3 ovarian cancer cell lines were treated with paclitaxel for 24 h
following FOXM1 depletion by siRNA, subjected to TUNEL assay and examined by
fluorescent microscopy. These two cell lines were chosen to study the role of FOXM1
on paclitaxel-mediated mitotic catastrophe (Jiang et al., 2011). The result showed
there was an increased number of multi-nucleated cells (arrow) in ovarian cancer cells
with FOXM1 knockdown (P=0.03 and 0.01, respectively) as revealed by DAPI
staining (Figure 2.8), suggesting FOXM1 depletion significantly enhanced
paclitaxel-mediated mitotic catastrophe in both SKOV-3 and OVCAR3. It is notable
that apoptosis was barely detectable in these paclitaxel-treated cells as shown by the
insignificant positive green staining of TUNEL assay (data not shown) This was
probably due to the fact that both SKOV-3 and OVCAR3 harbour dysfunctional p53,
and functional p53 is required for paclitaxel-induced apoptosis in ovarian cancer cells.
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Figure 2.8. Transient FOXM1 knockdown significantly enhanced
paclitaxel-induced mitotic catastrophe in SKOV-3 and OVCAR3 cells. SKOV-3
and OVCAR3 cells transfected with either siRNA pools against FOXM1 or control
siRNA pools were treated with paclitaxel (100nM) and stained with DAPI. Upper
panel: Representative staining results were shown showing that transient FOXM1
knockdown significantly enhanced paclitaxel-induced mitotic catastrophe (arrow) in
SKOV-3 and OVCAR3 cells respectively (Upper panel). Magnifications X400.
Lower panel: Graphs represent the results of 3 independent experiments, showing the
percentage of cells undergoing mitotic catastrophe, * P<0.05, significant;
Mann-Whitney U-test.
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2.4 Discussion
This is the first study demonstrating that high nuclear FOXM1 expression is
significantly correlated with stage, shorter overall survival and disease-free survival
of ovarian cancer patients. Multivariate analysis indicates that FOXM1 expression
could serve as an independent prognostic factor. Furthermore, transient FOXM1
depletion is capable of inhibiting ovarian cancer cell migration and invasion. These
findings suggest that FOXM1 can have a crucial role in ovarian carcinogenesis and
progression and may serve as a prognostic factor to predict patients' outcome.
Although FOXM1’s association with high grade ovarian cancer tumours has been
reported (Chan et al., 2012), whether FOXM1 contributes to the acquisition of
paclitaxel resistance remains undefined. Indeed, deregulated FOXM1 expression has
been shown to confer resistance to chemotherapeutic drugs such as cisplatin and
epirubicin (Kwok et al., 2010; Millour et al., 2011). This is attributable in part to the
regulation of DNA damage repair genes, particularly those involved in homologous
recombination, such as XRCC1, BRCA2, RAD51 and BRIP1 (Lam et al., 2013;
Monteiro et al., 2013; N. Zhang et al., 2012). Knockdown of FOXM1 is able to
re-sensitize drug resistance cancer cells to chemotherapy partly by suppressing the
activation of DNA damage repair genes (Lam et al., 2013; N. Zhang et al., 2012). In
view of the immunohistochemical finding suggesting association between FOXM1
and chemoresistance, a pair of established paclitaxel-sensitive and -resistant cell lines,
SKOV-3 and SKOV3-TR (Jiang et al., 2011), were recruited to study the effect of
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paclitaxel on FOXM1. Interestingly, paclitaxel treatment resulted in down-regulation
of FOXM1 in SKOV-3 but not in the resistant cell line SKOV3-TR, implying a role of
FOXM1 in mediating paclitaxel resistance in ovarian cancer cells.
Immunofluorescence study further showed transient FOXM1 knockdown could
enhance paclitaxel-mediated cell death in two ovarian cancer cell lines, SKOV-3
(deleted p53) (Hamroun et al., 2006) and OVCAR3 (mutant p53) (Wolf et al., 1999).
It is not surprising that apoptotic cells were barely detectable as both cell lines
harbour dysfunctional p53 while functional p53 is required for paclitaxel-induced
apoptosis in ovarian cancer cells. Recently, it has been suggested that the induction of
p53-independent apoptosis takes place through the activation of Caspase-9
(Yamakawa et al., 2008). However, immunoblotting revealed Caspase-9 was only
marginally activated upon paclitaxel treatment in SKOV-3 and SKOV-3-TR cells,
indicating that both paclitaxel and FOXM1 silencing induce cell death primarily
through enhancing mitotic catastrophe rather than apoptosis in ovarian cancer cells,
which commonly have dysfunctional p53 pathway. This is in line with previous
findings on paclitaxel in breast cancer (Wonsey & Follettie, 2005).
Immunofluorescence staining will also be performed in SKOV3-TR in future studies.
Mitotic catastrophe can be considered as a type of cell death occurring during mitosis
or resulting from mitotic failure (Castedo et al., 2004). Two mechanisms have been
proposed as crucial for mitotic catastrophe, namely the G2/M and mitotic spindle
checkpoints (Cahill et al., 1998). For the G2/M checkpoint, the inactivation of genes
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such as p53, p21Cip1 and 14-3-3Sigma have been reported to induce DNA
damage-induced mitotic catastrophe (Bunz et al., 1998; Chan et al., 1999). Flow
cytometric analysis performed in our study suggested FOXM1 knockdown in the
chemoresistant ovarian cancer cell line SKOV3-TR could induce G2/M arrest and
enhance paclitaxel-mediated cell death via mitotic catastrophe in a p53-independent
and Caspase-9-independent manner. Delineation of the underlying mechanism would
be informative and will be pursued in further studies.
In conclusion, overexpression of FOXM1 was found to be correlated with poor
patients' survival and to paclitaxel-mediated mitotic catastrophe in ovarian cancer
cells. Our findings help to define FOXM1 as a potential prognostic marker as well as
a therapeutic target in ovarian cancer.
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Chapter 3
Identification and characterization of KIF2C and KIF20A as
novel FOXM1 transcriptional targets
3.1 Introduction
3.1.1 Kinesin superfamily proteins (KIFs)
Intracellular trafficking is of utmost importance to normal cellular morphology and
function. After synthesis, lipids and proteins are sorted and transported to designated
locations within the cell as membranous organelles or protein complexes, whereas
mRNAs are carried in large protein complexes (Hirokawa, 1998). Three superfamilies
of molecular motors-kinesins, dyneins and myosins- have so far been identified (Vale,
2003).
First being isolated from squid nervous tissue in 1985 (Vale et al., 1985), kinesin
superfamily proteins (KIFs) are ubiquitously present in all eukaryotes. More than 40
KIFs have been identified to date and are classified into 15 families, which are named
kinesin 1 to kinesin 14B based on findings of phylogenetic analyses (Miki et al.,
2005). These families can be further grouped into three subtypes depending on the
location of the motor domain in the molecule. Motor domains are located in
N-kinesins, M-kinesins and C-kinesins in the amino-terminal region, the middle
region and the carboxy-terminal region respectively (Liu et al., 2013). Many motor
kinesins possess adenosine triphosphatase activity and microtubule-dependent
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plus-end motion ability. The highly conserved motor domain is responsible for motor
binding and stepping across microtubules by converting chemical energy generated
from ATP hydrolysis into mechanical force (Liu et al., 2013).
KIFs are not only involved in the intracellular transport of organelles, protein
complexes and mRNAs, but also play a crucial role in chromosomal and spindle
movements during mitosis and meiosis (Sharp et al., 2000). For instance, the activities
of microtubule motors on spindle microtubule are under precise regulation in order to
ensure that mitotic events are adequately orchestrated throughout the progression of
mitosis. Given the importance of proper sister chromatid separation during mitosis, it
comes with no surprise that dysregulated KIF proteins could result in aneuploid
daughter cells, eventually leading to the aggressive progression of cancer (Oki et al.,
2012). Indeed, accumulating evidence has been reported suggesting many KIF
members play critical roles in the genesis and development of various types of
cancers.
3.1.2 KIF2A
KIF2A belongs to the kinesin-13 family and is a microtubule depolymerase
responsible for ensuring proper bipolar spindle assembly during mitosis (Uehara et al.,
2013). KIF2A has been shown to control the length and alignment of central spindle
microtubules through depolymerization at their minus ends, and the distribution of
KIF2A is regulated by Aurora B activity gradient (Uehara et al., 2013). Recently,
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overexpression of KIF2A has been documented in squamous cell carcinoma of the
oral tongue (C. Q. Wang et al., 2010). Higher expression of KIF2A is also
significantly associated with lymph node metastasis and tumour stage. In Vitro
Transwell assay further demonstrated KIF2A silencing is capable of retarding the
migratory ability of cancer cells (C. Q. Wang et al., 2010). In another study, Li et al
reported that microRNA-183 (miR-183) directly inhibits the expression of KIF2A and
that ectopic expression of miR-183 could lead to significantly reduced cancer cell
migration and invasion, suggesting KIF2A plays a pivotal role in cancer metastasis
(Li et al., 2010).
3.1.3 KIF4A
KIF4A, a member of the kinesin-4 family, has also been widely reported to be
dysregulated in various cancer types. KIF4A expression is associated with shorter
survival for patients with non-small cell lung cancer, and KIF4A is capable of
regulating the growth of cancer cells as revealed by transient knockdown assays
(Taniwaki et al., 2007). However, contradictory findings regarding the role of KIF4A
in carcinogenesis have also been documented. For instance, Gao et al found
overexpression of KIF4A inhibits proliferation of human gastric carcinoma cells both
in vitro and in vivo (Gao et al., 2011). Thus, whether KIF4A possesses oncogenic or
tumour suppressing characteristics awaits further investigation.
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3.1.4 KIF11
KIF11 (or Eg5) is a member of the most conserved kinesin-5 family. With no
exception, KIF11 has also been suggested to contribute to the development of cancer.
KIF11 is found to be significantly associated with tumour stage, grade and poor
survival for patients with renal cell carcinoma (Sun et al., 2013). Up-regulation of
KIF11 has also been reported in pancreatic cancer cells (Sun et al., 2011).
Furthermore, overexpression of KIF11 could predict unfavorable prognosis in
non-muscle invasive bladder urothelial carcinoma (Ding et al., 2011).
3.1.5 KIF14
KIF14, a member of the kinesin-3 family, plays a crucial role in the cytokinesis of
eukaryotic cells. KIF14 is dysregulated in primary cancers including lung, breast,
hepatocellular carcinoma and retinoblastoma cancer (Basavarajappa & Corson, 2012).
In lung cancer, KIF14 overexpression is associated with shorter overall- and
disease-free survival, suggesting KIF14 could serve as an independent prognostic
marker (Corson et al., 2007). Ahmed et al reported that KIF14 negatively regulates
Rap1a-Radil signaling during breast cancer progression and that depletion of KIF14
could lead to enhanced cell spreading, altered focal adhesion dynamics as well as
inhibition of cell migration and invasion (Ahmed et al., 2012). Intriguingly, KIF14
mRNA has been reported to be an independent prognostic marker in serous ovarian
carcinoma (Theriault et al., 2012). In the same study, ectopic expression of KIF14
could increase proliferation and colony formation of ovarian cancer cells, suggesting a
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role of KIF14 in promoting tumorigenic phenotype (Theriault et al., 2012).
3.1.6 KIF15
KIF15 belongs to the kinesin-12 family. It has been reported KIF15 bound to
kinetochore fibers antagonizes centrosome separation while KIF15 bound to
non-kinetochore microtubules mediates centrosome separation (Sturgill & Ohi, 2013).
Whether KIF15 contributes to the genesis and development of cancer remains to be
answered.
3.1.7 KIFC3
KIFC3, a member of the kinesin-14B family, participates in the apical transport of
annexin XIIIb-associated Triton-insoluble membranes and plays a complementary
role in Golgi positioning and integration with cytoplasmic dynein (Noda et al., 2001;
Xu et al., 2002). A recent study showed ectopic expression of KIFC3 in breast cancer
cell lines could make the cells more resistant to docetaxel, indicating a role of KIFC3
in mediating docetaxel resistance in breast cancer cells (De et al., 2009).
3.1.8 KIF20A
KIF20A (or Rab6Kinesin) belongs to kinesin-6 family and is the first KIF to be
reported to bind to a Rab GTPase (Liu et al., 2013). Similar to other members of the
family, KIF20A is involved in cytokinesis and organelle transport (Liu et al., 2013).
Recent findings have been suggesting a pivotal role of KIF20A in the development of
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cancer. Transient knockdown of endogenous KIF20A expression in pancreatic ductal
adenocarcinoma cell lines has been demonstrated to be capable of drastically
attenuating growth of cancer cells, implying a role of KIF20A in pancreatic
carcinogenesis (Taniuchi et al., 2005). KIF20A has also been suggested as a novel
promising candidate for anticancer immunotherapeutic target for pancreatic cancers
(Imai et al., 2011). Furthermore, Gasnereau et al reported a strong accumulation of
KIF20A mRNA in a large series of human hepatocellular carcinomas, with the highest
expression observed in tumours harboring genomic instability (Gasnereau et al.,
2012). KIF20A has also been suggested to play a crucial role in mediating the
anti-cancer actions of genistein, and may thus be treated as a potential molecular
target for drug intervention of gastric cancer (Yan et al., 2012).
3.1.9 KIF20B
KIF20B, also known as M-phase phosphoprotein 1, acts as a mitotic molecular motor
crucial for faithful completion of cytokinesis (Abaza et al., 2003). Using a
genome-wide expression profile analysis, KIF20B has been demonstrated to be
significantly up-regulated in bladder cancer samples. In the same study, transient
knockdown of KIF20B resulted in a drastic increase in multinucleated cells and
cancer cell death, suggesting a role of KIF20B in the tumorigenesis of bladder cancer
(Kanehira et al., 2007). Recently, KIF20B has also been reported to contribute to
tumour cell growth and failed mitotic arrest (Liu et al., 2013).
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3.1.10 KIF2C
Being the founding and best-characterized member of the kinesin-13 family,
KIF2C/MCAK harbours an N-terminal domain, a positively charged neck followed
by the conserved kinesin motor domain and a C-terminal dimerization domain
(Sanhaji et al., 2011). Unlike other kinesin proteins, KIF2C depolymerizes
microtubules by disassembling tubulin units from the polymer end using energy
harnessed from ATP hydrolysis instead of moving directionally along microtubules
(Liu et al., 2013). This depolymerizing activity is of utmost importance in spindle
formation, correcting erroneous attachments of microtubule-kinetochore and in
chromosome movement. Therefore, an adequately orchestrated regulation of KIF2C is
crucial for ensuring the faithful segregation of chromosomes in mitosis and for
safeguarding chromosomal stability (Maney et al., 1998). Recent studies indicated
KIF2C is subjected to a complex spatio-temporal regulation during mitosis by Aurora
B, Aurora A, PLK1 and CDK1/Cyclin B1 (Sanhaji et al., 2011).
Given the pivotal roles of KIF2C in ensuring faithful progression of mitotic events, it
comes with no surprise that deregulation of KIF2C can result in aberrant mitosis,
chromosomal instability and ultimately cancer development. Indeed, KIF2C has been
established as one of the up-regulated genes in a genome-wide expression analysis of
81 breast cancer tissues using cDNA microarray laser capture microdissection
(Nishidate et al., 2004). Shimo et al further demonstrated KIF2C overexpression in
breast cancer cell lines as well as cancer tissues and that KIF2C expression can be
70
suppressed by ectopic expression of p53, suggesting a role of KIF2C in breast
carcinogenesis (Shimo et al., 2008). Elevated expression of KIF2C has also been
documented in gastric cancer (Nakamura et al., 2007). In the same study, elevated
KIF2C expression was also shown to be significantly associated with lymphatic
invasion, lymph node metastasis and poor survival of gastric cancer patients
(Nakamura et al., 2007). Recently, KIF2C has been reported to be up-regulated at
both mRNA and protein levels in colorectal cancer samples (Ishikawa et al., 2008).
Enhanced expression of KIF2C is markedly associated with lymph node metastasis,
venous invasion, peritoneal dissemination, Dukes' classification and poor survival rate
of colorectal cancer patients (Ishikawa et al., 2008). Taken together, KIF2C is
dysregulated in multiple cancer types and elevated KIF2C expression is correlated
with cancer invasiveness, metastasis and poor prognosis.
Intriguingly, KIF2C not only participates in the progression of cancer, but also has a
role in the development of taxane resistance. It has been reported that overexpression
of KIF2C confers resistance to paclitaxel (Ganguly et al., 2011). Using Chinese
hamster ovary (CHO) cells, it was further demonstrated that paclitaxel resistant cells
resulting from KIF2C overexpression shows a reduction in microtubule polymer and
an increase in the frequency of microtubule detachment from centrosomes.
Conversely, loss of KIF2C reverses the high frequency of microtubule detachment
and increases sensitivity of cells to paclitaxel (Ganguly et al., 2011).
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In view of the emerging role of KIFs in the acquisition of drug resistance, a
correlation analysis was performed to determine if KIFs could serve as potential
downstream targets of FOXM1 implicated in paclitaxel resistance of ovarian cancer
cells. Interestingly, KIF2C, KIF4A, KIF11, KIF15 and KIF20A appeared to have high
correlation scores with FOXM1 and are among the most probable target genes of
FOXM1. It is thus tempting to investigate if the KIFs (focusing on KIF2C) could be
established as novel FOXM1 transcriptional targets implicated in the acquisition of
paclitaxel resistance in ovarian cancer cells.
3.1.11 Aim:
1. To investigate the roles of KIF2C & KIF20A in the acquisition of paclitaxel
resistance in ovarian cancer cells
2. To establish KIF2C & KIF20A as candidate FOXM1 transcriptional targets in
mediating chemoresistance
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3.2 Materials and methods
3.2.1 Cell lines
A pair of paclitaxel-sensitive (PEO1) and -resistant (PEO1-TaxR) ovarian cancer cell
lines were used in the study (Jiang et al., 2011) instead of SKOV-3 and SKOV3-TR.
PEO1 and PEO1-TaxR are recently developed cell lines and have been authenticated
at Cancer Research UK facility. The use of PEO1 and PEO1-TaxR offers extra means
to ensure that resistant mechanisms identified in SKOV-3 and SKOV3-TR are
common to all paclitaxel resistant ovarian cancer cells and not unique to SKOV-3 and
SKOV3-TR. Importantly, both PEO1 and PEO1-TaxR are kept to lower passages to
avoid drifts in resistance and the acquisition of secondary mutations. PEO1 and
PEO1-TaxR were cultured in RPMI1640 (Sigma) supplemented with 10% foetal
bovine serum (FBS) and 100 units/ml penicillin-streptomycin (Invitrogen).
PEO1-TaxR is supplemented with 50nM of paclitaxel. All cell lines were maintained
at 37°C in humidified incubator with 5% CO2. Cell culture medium was changed
every 3 to 5 days depending on cell density. For routine passage, when cells reached
85% to 90% confluency, they were split at a ratio of 1:4.
3.2.2 Western blot
Cells were harvested with lysis buffer [0.125 m Tris, pH 6.8 at 22°C containing 1%
NP-40 (v/v), 2 mM ethylenediamine tetraacetic acid (EDTA), 2 mM
N-ethylmaleimide, 2 mM phenylmethanesulphonyl fluoride (PMSF), 1 mM sodium
orthovanadate and 0.1 μm sodium okadate] and centrifuged at 4°C for 10 min. Protein
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concentration was determined by detergent-compatible (DC) protein assay (Bio-Rad).
Twenty micrograms of protein were separated by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to
polyvinylidene difluoride membrane and hybridized with the following antibodies:
anti-FOXM1 (sc-502, Santa Cruz Biotechnology, CA, USA), anti-RAD51 (sc-8349.
Santa Cruz), anti-KIF2C (WH0011004M1, Sigma) and anti-β-tubulin (sc-9104, Santa
Cruz Biotechnology).
3.2.3 Transient overexpression of FOXM1 and transient knockdown of FOXM1
and KIF2C
For transient overexpression, cells were transfected with pcDNA3-FOXM1 and
control vector using Fugene 6 Transfection Reagent as per the manufacturer's
instructions (Roche Applied Science, IN, USA). ON-TARGET Plus Human FOXM1
siRNA, KIF2C siRNA and Non-targeting Control siRNAs (Thermo Scientific, CO,
USA) were employed for transient silencing using Oligofectamine transfection
reagent (Invitrogen) as previously described. Cells were harvested 72 h after
transfection.
3.2.4 RNA extraction
Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen, CA, USA).
Briefly, cells were lysed by continuous pipetting with 350μl of buffer RLT followed
by addition of equal volume of 70% ethanol. After binding to RNeasy Mini spin
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column, samples were washed sequentially with buffer RW1 and buffer RPE. RNA
was eluted with 50μl of RNase-free water.
3.2.5 Complementary DNA synthesis
Complementary DNA (cDNA) was synthesized by SuperscriptTM III First-Strand
synthesis System (Invitrogen). First, 1μl of 50μM oligo-(dT)20 and 1μl of 10mM
dNTP mix were added to 1μg of RNA and the final volume was made up to 13μl with
DEPC-treated water. The mixture was heated at 65°C for 5 minutes and chilled on ice
for 1 minute. Afterwards, 7μl of a synthesis mix containing 4μl of 5X first-strand
buffer, 1μl of 0.1M DTT, 1μl of RNaseOUTTM (40U/μl) and 1μl of Superscript III RT
(200U/μl) was added to each primer/RNA mixture. The sample mixtures were then
applied to the synthesizing reaction which was carried out at 50°C for 50 minutes and
terminated at 85°C for 5 minutes followed by brief chilling on ice.
3.2.6 Quantitative real-time PCR
Quantitative real-time PCR (qPCR) was performed using Power SYBR Green PCR
Master Mix (Applied Biosystems) and analysed by ABI7900 Sequence Detection
System (Applied Biosystems). Housekeeping gene L19 was used as internal control.
The following primers were used:
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Primer Forward 5' to 3' Reverse 5' to 3'
KIF2C CATGATTGCCACGATCTCAC CGTTAGAGCAGGCTTCCATC
KIF20A GCCAACTTCATCCAACACCT GTGGACAGCTCCTCCTCTTG
KIF4A ACCTCGCTGGATCAGAAAGA CACAAAGCCACCCTTTTTGT
KIF11 GGCAGTTGACCAACACAATG TCTAGCATGGCCTTTTGCTT
KIF15 AGGTGTTGTCTGGAGGATGG TTTGCCTTTCAGATCCTGTC
L19 GCGGAAGGGTACAGCCAAT GCAGCCGGCGCAAA
Table 3.1. Primers used in the analysis of expressions of KIFs upon FOXM1
knockdown
3.2.7 Cloning of pGL3-KIF2C and pGL3-KIF20A
Total DNA was purified from PEO1 cells using DNeasy Blood & Tissue Kit (Qiagen).
Two pairs of primers were designed to amplify a region 1.2kb upstream of the
transcription start sites of KIF2C and KIF20A respectively. Restriction digestion sites
for KpnI and HindIII were included in the primers. Pfu DNA polymerase (Promega)
was used in PCR to amplify the desired band, followed by agarose gel electrophoresis
and band purification using Wizard SV Gel and PCR Clean-Up System (Promega).
Restriction digestion was performed at 37°C for 4 h and ligation with pGL3 vector
was achieved at 16°C O/N using T4 DNA Ligase (New England Biolabs, UK).
Competent E.coli cells were then transformed with the ligated products and positive
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colonies were selected by restriction digestion to confirm the  insert. Plasmid
Maxiprep was used to generate ample amounts of pGL3-KIF2C and pGL3-KIF20A.
Primer Forward 5' to 3' Reverse 5' to 3'
KIF2C-Promoter GGGGTACCCCCGTCCGGGAGATGACGAG CCCAAGCTTGGGTTAAAACGTCATTCCGCT
KIF20A-Promoter GGGGTACCCCGACCGGGGTACCTATTCGTT CCCAAGCTTGGGCTGTCGTGGATTCGCACT
Table 3.2. Primers used in the cloning of pGL3-KIF2C and pGL3-KIF20A
3.2.8 Luciferase reporter assay
PEO1 cells seeded in 96-well plate were transfected FuGENE 6 Transfection Reagent
(Roche) with a mixture of pGL3-KIF2C/pGL3-KIF20A, renilla and an increasing
amount (0, 5, 10, 25, 50, 100 ng) of pcDNA3-FOXM1. Luciferase activity was
detected by steadylite plus system (PerkinElmer, MA, USA) after 24 h. Briefly, one
pot of luclite luciferase reagent was mixed with 10ml of luclite buffer, 10μl of 1M
MgCl2 and 5μl of 2M CaCl2. The reagent mixture was diluted with equal volume of
PBS and 100μl was applied to each well. After incubating at RT for 15 min in
darkness, cells were transferred to opaque plate for measuring fluorescence activity.
Afterwards, 25μl of renlite reagent (0.5M HEPES pH7.8, 40mM EDTA,
coelenterazine at 1mg/ml) was added to each well and the plate was incubated at RT
for 20 min in darkness followed by measurement. Relative reading was obtained by
dividing luciferase activity over renilla activity.
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3.2.9 Chromatin immunoprecipitation (ChIP)
40μl of Dynabeads Protein A (Invitrogen) was washed with 200μl of TSE I buffer for
three times and diluted with 40μl of TSE I buffer. Anti-FOXM1 (sc502, Santa Cruz
Biotechnology) (4μg) and rabbit IgG control (DAKO) (4μg) were first separately
diluted in Buffer D, mixed with diluted Dynabeads and then rotated O/N at 4。C. PEO1
and PEO1-TaxR cells at 90% confluency in 100mm culture dish were crosslinked
with 1% formaldehyde for 10 min, rinsed with ice-cold PBS and incubated with 2.5M
glycine for 5 min. Cells were then harvested with 2ml of scrapping buffer. After a
sequential wash with PBS, Buffer I and Buffer II, cell pellet was resuspended in 300μl
of Lysis buffer and subjected to sonication under optimized condition (20 min with
30s on and 30s off). Supernatant was then diluted in 300μl of Buffer D from which
100μl was taken as INPUT control. 200μl of cell lysate was mixed with prepared
Dynabeads and rotated O/N at 4°C. After a sequential wash with TSE I, TSE II,
Buffer III and TE buffer, 100μl of elution buffer was added to the Dynabeads and the
mixture was rotated at RT for 1 h. Eluted sample was collected in eppendorf and the
Dynabeads was re-eluted with another 100μl of elution buffer. 200μl of sample was
de-crosslinked by incubating at 65°C O/N. PCR Purification Kit (Qiagen) was then
used to purify DNA. Quantitative real-time PCR was performed with the following
primers: KIF2C (Forward 5' to 3': GCCAAGTCTCCAACTTGCTC; Reverse 5' to 3':
TTCCCAACCATCTTCCTACG).
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Buffer Composition
Buffer I 0.25% Triton X-100, 10mM EDTA,
0.5nM EGTA, 10mM HEPES pH6.5
Buffer II 200mM NaCl, 10mM EDTA, 0.5mM
EGTA, 10mM HEPES pH6.5
Buffer III
0.25M LiCl, 1% NP-40, 1%
deoxycholate, 1mM EDTA, 10mM
Tris-HCL pH8.1
Lysis buffer 1% SDS, 10mM EDTA, 50mM
Tris-HCL pH8.1
Buffer D 1% Triton X-100, 2mM EDTA, 20mM
Tris-HCL pH8.1, 150mM NaCl
TSE I
0.1% SDS, 1% Triton X-100, 2mM
EDTA, 20mM Tris-HCL pH8.1, 150mM
NaCl
TSE II
0.1% SDS, 1% Triton X-100, 2mM
EDTA, 20mM Tris-HCL pH8.1, 500mM
NaCl
TE buffer 10mM Tris-HCL pH8.0, 1mM EDTA
Scrapping buffer 100mM Tris-HCL pH9.4, 0.1% SDS
Elution buffer 0.1M NaHCO3, 1% SDS
Table 3.3. Composition of buffers used in ChIP
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3.2.10 Clonogenic assay
Transient knockdown of KIF2C was performed on PEO1 and PEO1-TaxR cells
seeded in 6-well plate. After 24 h, cells were re-seeded at a density of 1000 cells/well
and medium was changed after another 24 h supplemented with different
concentrations (0nM, 5nM, 10nM, 20nM) of paclitaxel. Fresh medium with drug was
changed every 3 days. Cells were fixed and stained with crystal violet after an
incubation of 14 days. Colonies were dissolved with 33% acetic acid and survival
rates were expressed as absorbance at 592nm.
3.2.11 Cell cycle analysis
Cell cycle analysis was performed by propidium iodide staining as described
previously (Kwok et al., 2008). Briefly, both adherent and suspension cells were
harvested and stained with propidium iodide (1mg/mL) in the presence of DNase-free
RNase for flow cytometric analysis. Cell cycle profile was analyzed by using the Cell
Diva software (Becton Dickinson UK Ltd.).
3.2.12 Statistical analysis
Statistical analysis was performed by the Statistical Package for Social Science
version 19.0 for Windows (IBM). Comparison between two groups of non-parametric
data was performed by Mann-Whitney U-test. P-values of <0.05 were considered to
be statistically significant.
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3.3 Results
3.3.1 Paclitaxel treatment downregulates the expression of FOXM1 in PEO1 but
not in the paclitaxel-resistant PEO1-TaxR
In view of the immunohistochemical data showing elevated FOXM1 expression was
associated with chemoresistance, a pair of established ovarian cancer cell line
sensitive and resistant to paclitaxel, namely PEO1 and PEO1-TaxR respectively, was
used to study the effect of drug treatment on the expression of FOXM1 as well as
some potential downstream targets. Cells were treated with paclitaxel (50nM) (the
optimum concentration for PEO1 and PEO1-TaxR which is different from SKOV-3
and SKOV3-TR) and harvested at various time points 0, 8, 16, 24, 48 and 72 h.
Immunoblotting showed FOXM1 expression to be up-regulated transiently at 8 h and
decreased at 48 h and 72 h in PEO1. However, FOXM1 expression remained
relatively constant at high levels in PEO1-TaxR upon paclitaxel treatment (Figure 3.1),
suggesting a role of FOXM1 in mediating paclitaxel resistance in ovarian cancer cells.
The expression of RAD51, an established downstream mediator of FOXM1 (N.
Zhang et al., 2012), also appeared to be down-regulated upon prolonged paclitaxel
treatment in the sensitive cell line. The reduced expression was not observed in the
resistant cell line. Intriguingly, protein expression of KIF2C showed a similar pattern
as that of FOXM1 with a transient up-regulation at 8 h and decrease at 48 h and 72 h
in PEO1. KIF2C level remained fairly constant in PEO1-TaxR.
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Figure 3.1. Representative immunoblots of FOXM1, RAD51 and KIF2C upon
paclitaxel treatment (50nM) at different time points (0h, 8h, 16h, 24h, 48h, 72h)
in sensitive ovarian cancer cell line PEO1 and paclitaxel-resistant cell line
PEO1-TaxR. Paclitaxel treatment down-regulated FOXM1 expression at time points
48h and 72h in PEO1 but not in PEO1-TaxR. Similar expression patterns were also
observed for RAD51 and KIF2C. Representative blot from three experiments.
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3.3.2 Transient knockdown of FOXM1 leads to down-regulations of KIF2C and
KIF20A
Since In silico analysis revealed correlation between FOXM1 and KIF superfamily of
proteins, quantitative real-time PCR (qPCR) was used to study the effects of transient
silencing and overexpression of FOXM1 on the transcript levels of selected KIF genes
including KIF2C, KIF4A, KIF11, KIF15 and KIF20A. Though ectopic expression of
FOXM1 did not lead to changes in expression of the five selected KIF genes, FOXM1
knockdown resulted in significantly down-regulated mRNA expressions of KIF2C
and KIF20A (P<0.05) (Figure 3.2). However, the transcript levels of KIF4A, KIF11
and KIF15 remained the same (Figure 3.3). Transient silencing of FOXM1 also
resulted in reduced protein expression of KIF2C in PEO1-TaxR (Figure 3.4).
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Figure 3.2. Quantitative real-time PCR analysis of the transcript levels of KIF2C
and KIF20A after transient silencing (NSC: Non-specific control) and
overexpression of FOXM1 (Over-C: control vector pcDNA3, Over-FOXM1:
pcDNA3-FOXM1) in ovarian cancer cell lines PEO1 and PEO1-TaxR.
Housekeeping gene L19 was used for normalization. Data represent triplicates from
three experiments. *P<0.05, ***P=0.0003. ns: not significant. Transient knockdown
of FOXM1 was capable of significantly down-regulating the expressions of KIF2C
and KIF20A.
KIF2C
NSC siFOXM1 Over-C Over-FOXM1
0.0
0.5
1.0
1.5
2.0
Re
lat
ive
 KI
F2
C m
RN
A e
xp
re
ss
ion
 le
ve
l
NSC siFOXM1 Over-C Over-FOXM10.0
0.5
1.0
1.5
Re
lat
ive
 KI
F2
C m
RN
A e
xp
re
ss
ion
 le
ve
lPEO1 PEO1-Ta
xR
*** *
ns
ns
NSC siFOXM1 Over-C Over-FOXM10.0
0.5
1.0
1.5
Re
lat
ive
 KI
F2
0A
 m
RN
A e
xp
re
ss
ion
 le
ve
l PEO1-TaxR
NSC siFOXM1 Over-C Over-FOXM10.0
0.5
1.0
1.5
Re
lat
ive
 KI
F2
0A
 m
RN
A e
xp
re
ss
ion
 le
ve
l PEO1
KIF20A
* *
ns ns
84
Figure 3.3. Quantitative real-time PCR analysis of the transcript levels of KIF4A,
KIF11 and KIF15 after transient silencing (NSC: Non-specific control) and
overexpression of FOXM1 (Over-C: control vector pcDNA3, Over-FOXM1:
pcDNA3-FOXM1). Housekeeping gene L19 was used for normalization. Data
represent triplicates from three experiments. ns: not significant. Transient
overexpression or silencing of FOXM1 appeared to have no effects on the expressions
of KIF4A, KIF11 and KIF15.
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Figure 3.4. Immunoblotting analysis demonstrating reduced expression of
KIF2C in PEO1-TaxR after FOXM1 knockdown. (NSC: Non-specific control;
siFOXM1: transient silencing of FOXM1). Representative blot from three
experiments.
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3.3.3 FOXM1 could activate the promoter of KIF2C but not KIF20A
Several FOXM1 consensus binding sites were identified in the promoter region of
KIF2C and KIF20A. In order to investigate if FOXM1 could transcriptionally activate
KIF2C and KIF20A, around 1.2kb region upstream of the transcription start sites of
KIF2C and KIF20A were separately cloned into pGL3 vector. The resulting
pGL3-KIF2C and pGL3-KIF20A were subjected to restriction enzyme digestion and
agarose gel electrophoresis to confirm the insert (Figure 3.5). Luciferase reporter
assay was then performed by titrating pGL3-KIF2C and pGL3-KIF20A with
increasing amounts (ng) of pcDNA3-FOXM1 at 0, 5, 10, 25, 50, 100. Empty pcDNA3
was used as control. While pGL3-KIF2C appeared to be gradually activated with
increasing amounts of pcDNA3-FOXM1 (P<0.05) as revealed by rising luciferase
reading, the activation of pGL3-KIF20A was not significant when compared to
control (Figure 3.6).
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Figure 3.5. Restriction digestion (XbaI and NotI) and agarose gel electrophoresis
of plasmids with inserts. Left: pGL3-KIF20A, Right: pGL3-KIF2C. 1.2kb region
upstream of the transcription start sites of KIF2C and KIF20A were separately
amplified and cloned into pGL3 vector. Positive clones containing pGL3-KIF2C and
pGL3-KIF20A were selected by restriction digestion and electrophoresis.
~1.2kb
~1.2kb
RE digestion of pGL3-KIF20ANEB 1kb ladder
RE digestion of pGL3-KIF2CNEB 1kb ladder
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Figure 3.6. Titration of pGL3-KIF2C with increasing amount (ng: 0, 5, 10, 25, 50,
100) of pcDNA3-FOXM1 (left) and titration of pGL3-KIF20A with increasing
amount (ng) of pcDNA3-FOXM1 (right). Data represent triplicates from three
experiments. *P<0.05, **P=0.006. ns: not significant. FOXM1 could activate the
promoter of KIF2C but not that of KIF20A. Treatments with different amount of
pcDNA3-FOXM1 (5-100ng) were compared individually to the treatment without
pcDNA3-FOXM1 (0ng). Comparison among different concentrations showed no
significant difference.
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3.3.4 FOXM1 is capable of binding to the promoter region of KIF2C
Given the findings that knockdown of FOXM1 resulted in down-regulation  of
KIF2C and that FOXM1 could activate the promoter of KIF2C as revealed by
Luciferase reported assay, chromatin immunoprecipitation (ChIP) was performed in
an attempt to evaluate if FOXM1 can bind to the promoter region of KIF2C.
ChIP-qPCR analysis showed significantly enhanced pull-down of KIF2C by
anti-FOXM1 antibody when compared to the IgG control in both PEO1 (51 folds
enrichment, P=0.04) and PEO1-TaxR (31 folds enrichment, P<0.0001) (Figure 3.7),
indicating FOXM1 is capable of binding to the promoter region of KIF2C.
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Figure 3.7. Chromatin immunoprecipitation-qPCR (ChIP-qPCR) revealing
significantly enhanced pull-down of KIF2C by anti-FOXM1 antibody as
compared to the negative IgG control.
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3.3.5 KIF2C knockdown appeares to re-sensitize PEO1-TaxR to paclitaxel
Clonogenic assay was used to investigate the role of KIF2C in the acquisition of
paclitaxel resistance in ovarian cancer cells. Following KIF2C knockdown and
paclitaxel treatment at various concentrations (0, 5, 10, 20nM) for a period of 14 days,
PEO1 and PEO1-TaxR cells were harvested and survival rates were measured in
terms of absorbance. Although no difference in survival was observed between
non-specific control (NSC) and KIF2C knockdown (siKIF2C) in PEO1 upon
paclitaxel treatment, there appeared to be lower survival rates in PEO1-TaxR
transfected with siKIF2C than PEO1-TaxR transfected with control upon paclitaxel
treatment (Figure 3.8), suggesting KIF2C might contribute to the development of
paclitaxel resistance in ovarian cancer cells. Efficacy of KIF2C knockdown was
confirmed by Western blot analysis (Figure 3.9).
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Figure 3.8. Clonogenic assay showing KIF2C knockdown appeared to
re-sensitize the PEO1-TaxR cells to paclitaxel treatment. NSC: non-specific
control; siKIF2C: KIF2C knockdown. Data represent triplicates from three
experiments.
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Figure 3.9. Western blot confirming the efficacy of KIF2C knockdown. NSC:
non-specific control; siKIF2C: KIF2C knockdown. Representative blot from three
experiments.
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3.3.6 KIF2C knockdown increases accumulation of cells at G2/M in PEO1 and
dead cells in PEO1-TaxR upon paclitaxel treatment
Cell cycle analysis was then performed to investigate the role of KIF2C in
paclitaxel-mediated cell death. To this end, PEO1 and PEO1-TaxR cells were
transiently transfected with non-specific control (NSC) and KIF2C siRNA (siKIF2C)
for 48 h and cultured in the presence of paclitaxel treatment (50nM) for 48 h. Cells
were then harvested, stained with propidium iodide and subjected to flow cytometric
analysis. The results showed that though not significant, KIF2C depletion by siRNA
decreased the number of dead cells in the sub-G1 population (18% vs 10.2%) and
increased the levels of G2/M cells in the PEO1 cells treated with paclitaxel as
compared to control (67% vs 53.1%) (Figure 3.10). Paclitaxel also induced a minor
increase in cell death (sub-G1 population) in PEO1-TaxR cells transfected with
KIF2C siRNA (3.42% vs 2.43%) (Figure 3.10).
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Figure 3.10. Flow cytometric analysis of PEO1 and PEO1-TaxR cells with and
without KIF2C depletion in the presence of paclitaxel treatment.
Upper panel: Flow cytometric analysis was performed following propidium iodide
staining on PEO1 and PEO1-TaxR cells treated with paclitaxel (50nM) after
transfection with siRNA pools against KIF2C. Data indicated that KIF2C silencing
(siKIF2C) is capable of decreasing the number of dead cells in the sub-G1 population
and increasing the number cells blocked at G2/M cell cycle phase in PEO1 and raising
the number of dead cells in PEO1-TaxR as compared to cells treated with control
(NSC). Lower panel: Bar charts of the cell cycle distribution of PEO1 and
PEO1-TaxR upon paclitaxel treatment after transfection with NSC or siKIF2C of an
independent experiment.
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3.4 Discussion
Kinesin superfamily proteins (KIFs) play pivotal roles in intracellular transport of
organelles and maintenance of spindle assembly during mitosis and meiosis.
Emerging evidence suggests dysregulations of KIF members contribute to
tumorigenesis of multiple types of human cancer. In this study, KIF2C (MCAK) was
identified as a novel transcriptional target of FOXM1 and KIF2C participates in the
acquisition of paclitaxel resistance in ovarian cancer.
In view of the bioinformatics analysis revealing a positive correlation between
FOXM1 and KIF proteins, several pairs of primers were designed and qPCR was used
to study whether FOXM1 affects the expressions of KIF proteins. Transient
knockdown of FOXM1 resulted in reduced mRNA expressions of KIF2C and KIF20A
but not of KIF4A, KIF11 and KIF15. The down-regulation at protein level was also
observed for KIF2C. However, ectopic expression of FOXM1 did not alter the
expressions of KIFs which might be attributable to the fact that ovarian cancer cells
already harbour high FOXM1 expression. This finding is in line with a microarray
analysis implying KIF20A to be a target gene of FOXM1 (Wonsey & Follettie, 2005).
Reporter plasmids containing the promoter regions of KIF2C and KIF20A were
subsequently cloned and Luciferase reporter assay was employed to study if FOXM1
can induce activation of the promoters. Upon titration of increasing amounts of
FOXM1, it was observed that only pGL3-KIF2C was activated but not pGL3-KIF20A,
indicating KIF2C may be a direct transcriptional target of FOXM1. Chromatin
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immunoprecipitation-qPCR (ChIP-qPCR) further demonstrated that FOXM1 could
bind to and pull-down KIF2C in ovarian cancer cell lines, indicating KIF2C may be a
novel transcriptional target of FOXM1.
Overexpression of KIF2C is not only associated with malignant progression, but also
with drug resistance (Sanhaji et al., 2011). It has been reported in a recent study
recruiting Chinese hamster ovary (CHO) cells that paclitaxel resistant cells resulting
from KIF2C overexpression displays a reduction in microtubule polymer and an
increase in the frequency of microtubule detachment from centrosomes. Conversely,
loss of KIF2C reverses the high frequency of microtubule detachment and increases
sensitivity of cells to paclitaxel (Ganguly et al., 2011). In the current study,
immunoblotting analysis showed KIF2C expression in PEO1 altered in a similar
pattern as FOXM1 expression by displaying an initial induction at 8 h followed by a
subsequent decrease at 48 h and 72 h upon paclitaxel treatment. In contrast, KIF2C
expression remained relatively constant in PEO1-TaxR, implicating KIF2C might be
involved in the development of paclitaxel resistance in ovarian cancer. Furthermore,
KIF2C knockdown is capable of re-sensitizing PEO1-TaxR to paclitaxel treatment as
revealed by clonogenic assay. Flow cytometric analysis showed KIF2C silencing is
able to induce cell cycle arrest at G2/M in PEO1 and increased cell death in
PEO1-TaxR. Further experiments are required to confirm the finding.
Taken together, this study identified KIF2C as a novel FOXM1 transcriptional target
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and KIF2C contributes to the acquisition of paclitaxel resistance in ovarian cancer
cells by inducing enhanced G2/M arrest and cell death. Site-directed mutagenesis
coupled with Luciferase reporter assay will be performed in future studies in order to
consolidate the interaction between FOXM1 and KIF2C. Functional experiments will
also be pursued to further understand the role of KIF2C in drug resistance.
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Chapter 4
Identification of PAK4 as a novel transcriptional target of
FOXM1
4.1 Introduction
4.1.1 p21-activated kinases (PAKs)
p21-activated serine/threonine kinases (PAKs) are identified as major effectors of the
small Rho GTPases Rac1 and Cdc42. Based on structural and functional similarities,
the six members of PAK family are classified into group I (PAK1, PAK2, PAK3) and
group II (PAK4, PAK5, PAK6) (Kumar et al., 2006). PAKs are evolutionarily
conserved and generally expressed in a variety of tissues playing pivotal roles in
morphogenesis, cytoskeletal reorganization, apoptosis, survival and angiogenesis
(Kumar et al., 2006). Over the years, accumulating evidence has suggested PAK
family members contribute to the processes of tumour formation and cell
invasiveness.
4.1.2 Group I PAKs
4.1.2.1 PAK1
Similar to other members of the PAK family, PAK1 consists of a C-terminal kinase
domain and an N-terminal regulatory domain containing a GTPase binding domain
and an inhibitory domain. When inactive as homodimers, the kinase inhibitory
domain of PAK1 binds to the other kinase domain keeping it in an inactive state.
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When bound by GTP-bound forms of Cdc42 and Rac, the inhibition is released
thereby allowing phosphorylation of the kinase domain and activation of PAK1
(Pirruccello et al., 2006). However, group I PAKs can also be activated in a
GTPase-independent manner. Regardless of the mode of activation, activated PAKs
phosphorylate their substrate proteins and in turn activate a myriad of biological
functions (Molli et al., 2009).
PAKs participate in cytoskeleton remodeling by phosphorylating a wide array of
downstream effectors involved in regulation of cytoskeletal structure including
LIM-kinases (LIMK), paxillin, filamin A, cortactin, myosin light-chain kinase
(MLCK), PIX/COOL guanine nucleotide exchange factors, stathmin and tubulin
cofactor B (Kumar et al., 2006). The forkhead box transcription factors (FOXs),
estrogen receptor α (ERα), Snail homologue 1 and C-terminal binding protein 1
(CtBP1) have also been identified as PAK1-interacting substrates involved in crucial
biological processes such as epithelial-mesenchymal transition (EMT) (Come et al.,
2004; Grooteclaes & Frisch, 2000).
In addition to regulating cytoskeletal reorganization, PAK1 also plays an important
role in the faithful progression of cell cycle. For instance, it has been demonstrated
cyclin B1/Cdc2 mediated phosphorylation of PAK1 during mitosis is crucial for cell
division (Thiel et al., 2002). Li et al reported that activated PAK1 is specifically
localized within chromosomes during prophase and on centrosomes during metaphase
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before moving to the contraction ring during cytokinesis (Li et al., 2002). An
interaction between PAK1 and histone H3 has also been shown in the same study (Li
et al., 2002). Furthermore, PAK1 has been documented to bind to and phosphorylate
Aurora-kinase A and polo-like kinase 1 (PLK1), suggesting the importance of PAK1
in cell-cycle checkpoints and adequately orchestrated cell-cycle progression (Maroto
et al., 2008; Zhao et al., 2005).
PAK1 is responsible for modulating cell survival via multiple mechanisms.
Schurmann et al demonstrated PAK1 phosphorylates Bad in vitro and in vivo on
Ser-112 and Ser-136, resulting in a markedly reduced interaction between Bad with
Bcl2 family members and thus an anti-apoptotic action (Schurmann et al., 2000).
Under apoptotic stimuli, however, PAK1 can phosphorylate dynein light chain 1
(DLC1) and BimL leading to inactivation of the anti-apoptotic function of Bcl2
(Vadlamudi et al., 2004). Furthermore, PAK1 has been reported to be an important
mediator of estrogen's cell survival functions by phosphorylating and inactivating the
forkhead transcription factors, thereby exerting an anti-apoptotic function (Mazumdar
& Kumar, 2003).
In recent years, an emerging body of evidence has indicated a crucial role of PAK1 in
the carcinogenesis of a broad spectrum of cancers. PAK1 amplification is prevalent in
luminal breast cancer, and PAK1 protein expression is significantly associated with
lymph node metastasis (Ong et al., 2011). PAK1 hyperactivation has also been shown
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to enhance the stimulation of downstream effectors MEK1/2 and p38-MAPK in
mammary tumour epithelial cells (Wang et al., 2006). Overexpression of PAK1 is also
detected in 70% of colon cancer samples and is associated with multiple signaling
pathways including Wnt, Erk and Akt pathways (Ye & Field, 2012). Down-regulation
of PAK1 has been reported to be able to reduce β-catenin accumulation and
proliferation of colon cancer cells (Zhu et al., 2012). Strong nuclear and cytoplasmic
PAK1 expression is observed in squamous non-small cell lung carcinomas (NSCLCs).
Selective PAK1 inhibition could postpone cell-cycle progression both in vitro and in
vivo (Molli et al., 2009). Siu et al further identified PAK1 as an independent
prognostic factor in ovarian cancer, affecting cell migration and invasion via p38
pathway (Siu et al., 2010a).
4.1.2.2 PAK2
PAK2 can affect both cell survival and cell death pathways depending on cellular
contexts. Cellular stresses such as DNA damage and serum starvation activate PAK2
to generate a proteolytic fragment, PAK-2p34, and lead to apoptosis (Roig & Traugh,
1999). In contrast, Activation of full-length PAK2 is capable of promoting cell
survival by phosphorylating Bad and enhancing the interaction between Bad and
14-3-3tau, thereby promoting cell survival (Jakobi et al., 2001).
Although less well characterized than PAK1, increasing attention has been drawn to
the oncogenic role of PAK2. Up-regulation of phosphorylated PAK2 (pPAK2) has
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been documented in ovarian cancer cell lines, and transient knockdown of PAK2
could retard cancer cell migration and invasion (Siu et al., 2010a). Recently,
clinicopathological analyses indicated that the phosphorylation level of PAK2 is
closely correlated with tumour progression, metastasis and early recurrence of
hepatocellular carcinoma (Sato et al., 2013). The same study also suggested PAK2
may serve as a critical mediator of TGF-β-mediated hepatoma cell migration, thus
establishing PAK2 as a promising target for the treatment of hepatocellular carcinoma
(Sato et al., 2013).
4.1.2.3 PAK3
With no exception, PAK3 is also involved in the regulation of cytoskeleton dynamics.
Hashimoto et al reported paxillin is the sole member among several representative
focal adhesion proteins that associates with PAK3. paxillin alpha was further shown to
be capable of linking both the kinase-inactive and activated forms of PAK3 to
integrins (Hashimoto et al., 2001). It has been documented that PAK3 positively
regulates Raf-1 activity through phosphorylation of Ser-338 (King et al., 1998).
NADPH oxidase is an enzyme responsible for regulating the intracellular context of
reactive oxygen species (ROS). PAK3 has been shown to confer survival advantage to
cancer cells by activating NADPH oxidase and thus altering the redox potential of
cells (Molli et al., 2009). There has been little data regarding whether PAK3
participates in the development of cancer, though overexpression of PAK3 has been
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found in thymic neuroendocrine tumours (Liu et al., 2010). Intriguingly, PAK3 is the
sole member of the group I PAKs known to be associated with a human genetic
disease. Mutations in the PAK3 gene have been reported in X-linked non-syndromic
mental retardation syndromes in which an A365E mutation adversely affects a highly
conserved region of PAK3 (Gedeon et al., 2003).
4.1.3 Group II PAKs
Group II PAKs consists of PAK4, PAK5, PAK6 and are structurally distinct from
group I PAKs. They merely contain an N-terminal p21-binding domain and a
C-terminal kinase domain but lack other motifs generally found in group I PAKs
(Molli et al., 2009). Although interaction of group II PAKs with GTPases barely has
an effect on kinase activity, PAK4-6 do play vital roles in a broad spectrum of
biological processes including cell motility and survival (Molli et al., 2009).
4.1.3.1 PAK5
The constitutively active PAK5 (also known as PAK7) binds to the GTPases Cdc42
and Rac and antagonizes Rho in the pathway, resulting in filopodia formation and
neurite development (Dan et al., 2002). Timm et al demonstrated PAK5 contributes to
microtubule stability by preventing MARK (a kinase promoting microtubule
disruption)-induced phosphorylation of tau (Timm et al., 2006). PAK5 has also been
reported to be constitutively localized to mitochondria and inhibit apoptosis by
phosphorylating Bad (Cotteret et al., 2003).
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Studies focusing on the role of PAK5 in carcinogenesis are on the rise.
Overexpression of PAK5 has been shown in a range of colorectal carcinoma cell lines
and the elevated expression is significantly associated with metastatic foci, high
cancer grades and poor differentiation of colorectal cancer (Gong et al., 2009). The
same investigators then documented elevated expression of PAK5 is capable of
antagonizing camptothecin-induced apoptosis by inhibiting the activity of caspase-8
in colorectal carcinoma cell lines (X. Wang et al., 2010). Transient silencing of PAK5
has been reported to inhibit human gastric cancer cell proliferation by inducing cell
cycle arrest in G(0)/G(1) phase (Gu et al., 2013). An oncogenic role of PAK5 has also
been observed in glioma cells (Han et al., 2013). Interestingly, PAK5 expression was
found to be correlated with advanced stages and high grades of epithelial ovarian
cancer and contribute to the acquisition of paclitaxel resistance of ovarian cancer cells
(Li et al., 2013).
4.1.3.2 PAK6
PAK6 is a 75-kDa protein harbouring an N-terminal Cdc42/Rac binding motif and a
C-terminal kinase domain (Yang et al., 2001). PAK6 is highly expressed in the brain
and although PAK6 double knockout mice remained viable and fertile, they displayed
several locomotor and behavioral deficits, suggesting PAK6 is important for certain
neuronal functions (Minden, 2012). Zhao et al further demonstrated PAK6 is involved
in central nervous system pathophysiology after traumatic brain injury (W. Zhao et al.,
2011).
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Similar to other PAKs, PAK6 also participates in the development of multiple types of
cancer. Overexpression of PAK6 has been observed in both primary and metastatic
prostate cancer cells and contributes to prostate cancer progression post androgen
deprivation therapy (Kaur et al., 2008). Recently, it has been shown knockdown of
PAK6 inhibits prostate cancer growth and enhances chemosensitivity to docetaxel
(Wen et al., 2009). Whether PAK6 contributes to the carcinogenesis of other cancer
types awaits further investigation.
4.1.3.3 PAK4
PAK4 is the first identified and most intensively studied member of group II PAKs,
serving a pivotal role in a wide array of cellular functions. PAK4 is an effector of
Cdc42 crucial for regulating cytoskeleton reorganization (Kumar et al., 2006). PAK4
also phosphorylates LIMK1 and enhances its ability to phosphorylate cofilin thereby
modulating cytoskeletal changes (Dan et al., 2001). Activated PAK4 is capable of
protecting cells from apoptosis by phosphorylating Bad and by inhibiting caspase
activation (Gnesutta et al., 2001). Qu et al reported activated PAK4 regulates cell
adhesion and anchorage-independent growth (Qu et al., 2001).
Though PAK4 is highly expressed in embryos, its protein levels are generally low in
adult tissues. Taken into account the finding that PAK4 null mice are embryonic lethal,
PAK4 is indispensible for embryonic development (Qu et al., 2003). Early death of
PAK4 null embryos is due in part to abnormal growth and branching of blood vessels,
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suggesting a role of PAK4 in angiogenesis (Qu et al., 2003). PAK4 also participates in
the normal functioning of heart. For instance, it has been documented PAK4 null
embryos harbour a thinning of the myocardial walls of the bulbus cordis and the
ventricle, and dilation as well as distortion of the sinus venosus region of the heart has
been observed (Qu et al., 2003). Nekrasova et al further demonstrated knockdown of
PAK4 in cultured cardiomyocytes could lead to severely compromised sarcomeric
structure and deficits in contraction, emphasizing PAK4 is crucial for normal
development of the heart (Nekrasova & Minden, 2012).
Given the pivotal roles of PAK4 in a broad spectrum of biological processes, it comes
with no surprise that dysregulation of PAK4 could result in oncogenic transformation.
In athymic mice, overexpression of PAK4 results in tumour formation and depletion
of PAK4 inhibits tumorigenesis (Liu et al., 2008). In fact, PAK4 is up-regulated in
most cancer cell lines (Callow et al., 2002). This is in contrast to a generally low
PAK4 expression in most normal tissues. In addition to cell lines, PAK4 has been
reported to be elevated in many primary tumours. PAK4 overexpression has been
documented in a subset of gastric cancer cell lines, and patients with high PAK4
expression tend to have poor survival rates (Ahn et al., 2011). Increased level of
PAK4 was also detected in hepatocellular carcinoma samples (Minden, 2012). Mak et
al showed overexpression of CDK5 kinase regulatory subunit-associated protein 3
(CDK5RAP3) promotes hepatocellular carcinoma metastasis through PAK4 activation
(Mak et al., 2011). Recently, the microRNA miR-199a/b-3p was found to be
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consistently down-regulated in hepatocellular carcinoma and miR-199a/b-3p can
target PAK4 to suppress growth of cancer cells (Hou et al., 2011). An oncogenic role
of PAK4 has also been reported in breast and endometrial cancer (Lu et al., 2013;
Wong et al., 2013).
Ovarian cancer cell lines have also been reported to have high levels of PAK4.
Elevated expressions of PAK4 and phospho-PAK4 are significantly associated with
metastasis of ovarian cancer, shorter survival, advanced stage as well as reduced
chemosensitivity (Siu et al., 2010b). Knockdown of PAK4 in ovarian cancer cell lines
retards cell migration, invasion and proliferation whereas ectopic expression of PAK4
has the opposite effect (Siu et al., 2010b).
Since PAK4 plays an important role in the acquisition of drug resistance, a
correlation analysis was performed to determine if FOXM1 could regulate PAK4
which might contribute to paclitaxel resistance of ovarian cancer cells. Interestingly,
PAK4 appeared to have high correlation score with FOXM1 and is a potential target
gene of FOXM1. It is thus tempting to investigate if the PAK4 could be established as
novel FOXM1 transcriptional targets that might be implicated in the acquisition of
paclitaxel resistance in ovarian cancer cells.
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4.1.4 Aim:
1. To elucidate the role of PAK4 in acquisition of paclitaxel resistance in ovarian
cancer
2. To study if PAK4 expression correlates with FOXM1 expression in ovarian cancer
tissue samples
3. To investigate if FOXM1 is able to transcriptionally regulate PAK4
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4.2 Materials and methods
4.2.1 Cell lines
The paclitaxel-sensitive ovarian cancer cell line PEO1 and -resistant cell line
PEO1-TaxR were used in the study. Cell culture conditions were the same as
mentioned in chapter 3.
4.2.2 Immunohistochemistry (IHC)
Immunohistochemical staining of FOXM1 was performed in chapter 3.
Immunohistochemical staining of PAK4 was done independently in a separate project
and the data has been published (Siu et al., 2010b). New PAK4 staining images were
captured with agreement of the authors.
4.2.3 Transient knockdown of FOXM1
ON-TARGET Plus Human FOXM1 siRNA and Non-targeting Control siRNAs
(Thermo Scientific, CO, USA) were employed for transient silencing of FOXM1 and
control using Oligofectamine transfection reagent (Invitrogen).
4.2.4 RNA extraction
Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen, CA, USA)
as described above.
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4.2.5 Complementary DNA (cDNA) synthesis
Complementary DNA (cDNA) was synthesized by SuperscriptTM III First-Strand
synthesis System (Invitrogen) as described above.
4.2.6 Quantitative real-time PCR
Quantitative real-time PCR (qPCR) was performed using Power SYBR Green PCR
Master Mix (Applied Biosystems) and analysed by ABI7900 Sequence Detection
System (Applied Biosystems). Housekeeping gene L19 was used as internal control.
The following primers were used:
Primer Forward 5' to 3' Reverse 5' to 3'
PAK4 ATGTGGTGGAGATGTACAACAGCTA GTTCATCCTGGTGTGGGTGAC
L19 GCGGAAGGGTACAGCCAAT GCAGCCGGCGCAAA
Table 4.1. Primers used in qPCR analysis of PAK4
4.2.7 Western blot
Immunoblotting was performed as described above. The following antibodies were
used: anti-PAK4 (#3242, Cell Signaling), anti-β-tubulin (sc-9104, Santa Cruz
Biotechnology).
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4.2.8 Cloning of pGL3-PAK4
Generation of reporter plasmid pGL3-PAK4 was performed similarly to the cloning of
pGL3-KIF2C and pGL3-KIF20A. Briefly, a pair of primer with restriction sites (KpnI
and HindIII) was designed to amplify a region 1.2kb upstream of the transcription
start sites of PAK4. The resulting product was purified and ligated to pGL3 vector.
Following transformation, colonies were picked and restriction digestion was used to
confirm positive clones harbouring pGL3-PAK4. The following primers were used:
Primer Forward 5' to 3' Reverse 5' to 3'
PAK4-Promoter GGGGTACCGGAATGCAGCAGTGAACAAA CCCAAGCTTAGTTAGGGGCTGGGAGAAAG
Table 4.2. Primers used in the cloning of pGL3-PAK4
4.2.9 Luciferase reporter assay
Luciferase reporter assay was done as described above.
4.2.10 Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation (ChIP) was done as described above. qPCR was
performed using the following primer: PAK4 ChIP Forward 5' to 3':
CCGACCTCCACTACAACTCC; PAK4 ChIP Reverse 5' to 3':
CAGACAGACCAGCGTTCAAA.
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4.2.11 Statistical analysis
Statistical analysis was performed by the Statistical Package for Social Science
version 19.0 for Windows (IBM). Comparison between two groups of non-parametric
data was performed by Mann-Whitney U-test. Correlation analysis was achieved by
Pearson's correlation test. Probability of survival was analyzed using the
Kaplan-Meier approach. P-values of <0.05 were considered to be statistically
significant.
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4.3 Results
4.3.1 Nuclear FOXM1 immunohistochemical staining correlates with total PAK4
expression and the co-expression of FOXM1 and PAK4 is a poor prognostic
factor for ovarian cancer patients
In order to evaluate if FOXM1 expression correlates with PAK4 expression in ovarian
cancer tissue samples, previous PAK4 immunohistochemical stainings and scores
were retrieved (Siu et al., 2010b). Although no correlation was observed between
nuclear FOXM1 and nuclear PAK4 expressions, using cutoffs of 3 and 4.8 for nuclear
FOXM1 IHC score and total PAK4 scores (a sum of PAK4 nuclear and cytoplasmic
scores) respectively, nuclear FOXM1 expression was found to be significantly
correlated with total PAK expression (P=0.021) (Figure 4.1). Representative images
were re-captured from archival PAK4 tissue slides and a similar staining pattern was
observed between nuclear FOXM1 and total PAK4 (Figure 4.2). Furthermore, the
high co-expression of nuclear FOXM1 and total PAK4 is significantly associated with
shorter overall survival (P=0.028) and disease-free survival (P=0.026) of ovarian
cancer patients (Figure 4.3).
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Figure 4.1. Pearson's correlation analysis demonstrating a significant correlation
between nuclear FOXM1 expression and total PAK4 expression. Nuclear
FOXM1 score was found to be significantly correlated with total PAK4 score (a
sum of PAK4 nuclear and cytoplasmic scores) in ovarian cancer patient samples.
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Figure 4.2. Representative IHC images showing a similar staining pattern
between nuclear FOXM1 and total PAK4 in ovarian cancer tissue slides.
Magnifications X400. Close correlation between FOXM1 and PAK4 stainings in
selected sample tissues confirmed the correlation between IHC scores.
Anti-FOXM1 Anti-PAK4
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Figure 4.3. Kaplan-Meier analysis showing high co-expression of high nuclear
FOXM1 and total PAK4 significantly correlates with poor overall and
disease-free survival of ovarian cancer patients.
P=0.028
P=0.026
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4.3.2 Paclitaxel treatment down-regulates PAK4 expression at 48 and 72 h in
PEO1 but not in PEO1-TaxR
PEO1 and PEO1-TaxR were treated with paclitaxel (50nM) and cells were harvested
at various time points (0, 8, 16, 24, 48, 72 h). Immunoblotting analysis showed PAK4
expression is reduced at 48 and 72 h in PEO1 while remaining fairly constant in
PEO1-TaxR (Figure 4.4).
Figure 4.4. Western blot analysis showing PAK4 expression is reduced at 48 and
72 h only in PEO1 but not in PEO1-TaxR. Representative blot was shown from
three experiments.
PAK4
βTubulin
PEO1 PEO1-TaxR
0 8 16 24 48 72 0  8 16  24  48 72 h
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4.3.3 FOXM1 knockdown results in mildly reduced PAK4 expression
Transient FOXM1 knockdown resulted in a mild reduction in PAK4 protein
expression as shown by Western blot analysis (Figure 4.5). However, Transcript level
of PAK4 remained unchanged upon FOXM1 silencing as shown by qPCR (Figure
4.5).
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Figure 4.5. Immunoblotting (upper panel) and qPCR (lower panel) showing the
effects of FOXM1 knockdown on protein and mRNA expressions of PAK4
respectively. Western blot analysis showed FOXM1 knockdown reduced PAK4
protein expression in PEO1-TaxR. PAK4 transcript level was unaffected upon
FOXM1 silencing. Data represent triplicates from three experiments. ns: not
significant.
4.3.4 FOXM1 can activate the promoter of PAK4
Several FOXM1 consensus binding sites were identified in the promoter region of
PAK4. In order to investigate if FOXM1 could transcriptionally activate PAK4,
around 1.2kb region upstream of the transcription start site of PAK4 was cloned into
pGL3 vector. The resulting pGL3-PAK4 was subjected to restriction enzyme digestion
and agarose gel electrophoresis to confirm the insert (Figure 4.6). Luciferase reporter
assay was then performed  by titrating pGL3-PAK4 with increasing amounts of
pcDNA3-FOXM1 (0, 5, 10, 15, 20 ,25 ng). Empty pcDNA3 was used as control.
pGL3-PAK4 appeared to be gradually activated in PEO1 cells with increasing
amounts of pcDNA3-FOXM1 as revealed by rising luciferase reading (Figure 4.7).
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Figure 4.6. Restriction digestion and agarose gel electrophoresis to select positive
clones containing pGL3-PAK4 reporter plasmid. 1.2kb region upstream of the
transcription start site of PAK4 was amplified and cloned into pGL3 vector. Positive
clone containing pGL3-PAK4 was selected by restriction digestion and
electrophoresis.
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Figure 4.7. pGL3-PAK4 appeared to be gradually activated upon titration with
increasing amount (0, 5, 10, 15, 20, 25 ng) of pcDNA3-FOXM1 in PEO1 cells.
Luciferase reporter assay demonstrated FOXM1 could activate the promoter region of
PAK4.
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4.3.5 FOXM1 is capable of binding to the promoter region of PAK4
Given the finding that FOXM1 could activate the promoter of PAK4 as revealed by
Luciferase reported assay, chromatin immunoprecipitation (ChIP) was performed in
an attempt to evaluate if FOXM1 can bind to the promoter region of PAK4.
ChIP-qPCR analysis showed significantly enhanced pull-down of PAK4 by
anti-FOXM1 antibody when compared to the IgG control in both PEO1 and
PEO1-TaxR (Figure 4.8), indicating FOXM1 is capable of binding to the promoter
region of PAK4.
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Figure 4.8. Chromatin immunoprecipitation (ChIP)-qPCR showing FOXM1 is
able to bind to the promoter region of PAK4 in PEO1 and PEO1-TaxR.
ChIP-qPCR analysis demonstrated anti-FOXM1 enhanced the pull-down of PAK4 as
compared to the negative IgG control.
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4.4 Discussion
Although no apparent association was observed between nuclear FOXM1 expression
and nuclear PAK4 expression in this study, nuclear FOXM1 expression displays a
significant positive correlation with total PAK4 level as revealed in the
immunohistochemical study. Indeed, elevated nuclear and cytoplasmic PAK4
expression has been shown to be associated with shorter overall and disease-free
survival of ovarian cancer patients (Siu et al., 2010b). In addition to playing an
important role in the regulation of actin cytoskeleton (Callow et al., 2005), nuclear
PAK4 has also been documented to promote gene transcription by modulating
β-catenin signaling (Y. Li et al., 2012). FOXM1 may thus be implicated in the
regulation of both the nuclear as well as cytoplasmic functions of PAK4. Transient
silencing of FOXM1 resulted in reduced PAK4 protein expression in PEO1-TaxR.
Surprisingly, no change in PAK4 transcript level was observed upon FOXM1
knockdown. This could be attributed to the fact that PAK4 has stable mRNA and
unstable protein. Indeed, it has been documented that mRNA correlates poorly with
protein levels and only about 40% of protein levels in cultured cells could be
explained by mRNA levels (Schwanhausser et al., 2011).
In an attempt to elucidate whether FOXM1 is able to transcriptionally activate PAK4,
luciferase reporter assay and chromatin immunoprecipitation studies were performed.
Intriguingly, FOXM1 is capable of pulling down PAK4 and inducing activation of the
promoter region of PAK4, indicating PAK4 might serve as a novel transcriptional
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target of FOXM1. Furthermore, paclitaxel treatment and immunoblotting showed
PAK4 expression follows a similar pattern to FOXM1 expression by displaying a
reduction at 48 and 72 h only in the sensitive PEO1 cells, but not in the resistant
PEO1-TaxR cells, suggesting a role of PAK4 in the development of paclitaxel
resistance in ovarian cancer cells. This is in line with a recent study demonstrating
overexpression of PAK4 is significantly associated with resistance to chemotherapy in
ovarian cancer (Siu et al., 2010b). In figure 4.4, the level of PAK4 expression in
PEO1-TaxR at time point 0 is comparable to that in PEO1 at time point 0. On the
other hand, a higher expression of PAK4 in non-specific control (NSC) of
PEO1-TaxR than that of PEO1 was shown in figure 4.5. Possible reasons may include
use of scrambled control in experiments of figure 4.5 but not in that of figure 4.4.
Recently, PAK4 was found to be involved in the regulation of the G1 phase and the
G2/M transition of the cell cycle. PAK4 is also crucial for metaphase spindle
positioning and anchoring (Bompard et al., 2013). Future experiments will focus on
how FOXM1 contributes to cell cycle progression through regulation of PAK4
transcription.
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Chapter 5
Up-regulation of hsa-miR-590 and hsa-miR-370 in
chemoresistant breast and ovarian cancer cells
5.1 Introduction
5.1.1 MicroRNA
Ever since the discovery of lin-4 in the nematode Caenorhabditis elegans (C.elegans)
in 1993, members of the novel class of small non-coding single strand regulatory
RNAs , the microRNA (miRNA) family, have been expanding (Chaudhuri &
Chatterjee, 2007). miRNAs are comprised of approximately 22 nucleotides and are
found in a diverse array of organisms ranging from prokaryotes, eukaryotes to viruses.
miRNAs could be either encoded by specific genes or located in the introns or exons
of protein-coding genes and expressed as a by-product (Chaudhuri & Chatterjee,
2007). They play crucial roles in a wide spectrum of cellular and physiological
functions, including cell proliferation, cell death, metabolism, haematopoiesis,
chromatin modification by modulating the expression of target genes (Alvarez-Garcia
& Miska, 2005).
5.1.2 Biogenesis and mechanism of action of miRNAs
Biogenesis of miRNAs in vertebrates initiates with the generation of a long primary
miRNA (pri-miRNA) which is transcribed mostly by RNA polymerases type II
(Pol-II). Each pri-miRNA is then processed into hairpin-shaped precursor miRNA
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(pre-miRNA) of approximately 60-70 nucleotidxes by Drosha-like RNase III
endonucleases (Borchert et al., 2006). The pre-miRNA is subsequently transported
out of nucleus into cytoplasm by Exportin-5 and Ran-GTP, and is then cleaved by
Dicer-like RNase III endonuclease to form the mature miRNA duplex. Afterwards,
one strand is usually incorporated into the RNA-induced silencing complex (RISC)
whereas the other strand is degraded (Borchert et al., 2006). Regulation of gene
expression is mediated through the canonical base pairing of miRNA seed sequence
and the complementary sequence of target mRNAs followed by silencing or
degradation of target mRNAs (Inui et al., 2010). It has been reported an average
miRNA has approximately 100 target sites, indicating that miRNAs are capable of
regulating a large fraction of protein-coding genes (Brennecke et al., 2005).
5.1.3 miRNAs and cancer
Since a large proportion of the transcriptome is subjected to miRNA regulation, It
comes with no surprise that alterations in miRNA expressions contribute to the
pathogenesis of many cancer types. Indeed, dysregulated miRNAs have been
documented in chronic lymphocytic leukemia (Mraz & Pospisilova, 2012), breast
cancer (F. Wang et al., 2010), lung cancer (Sotiropoulou et al., 2009), colorectal
cancer (Yang et al., 2009), prostate cancer (Walter et al., 2013), ovarian cancer (Iorio
et al., 2007), etc. Recently, accumulating evidence suggests that dysregulations of
miRNAs might play an important role in tumorigenesis, metastasis and
chemoresistance (Sotiropoulou et al., 2009). For example, overexpression of miR-451
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has been reported to increase the sensitivity of MCF-7 and resistant breast cancer cells
to doxorubicin (Kovalchuk et al., 2008). Distinct miRNA fingerprint has also been
associated with ovarian cancer drug resistance as revealed by high-throughput
profiling analysis (Sorrentino et al., 2008).
5.1.4 miR-590
Located on chromosome 7q11.23, hsa-miR-590 is but one member of the microRNA
family whose roles in orchestrating normal cellular functions as well as cancer
development have been drawing accumulating research focus. For instance, Eulalio et
al. recently reported miR-590 could promote cardiomyocyte proliferation in both
neonatal and adult animals, thus establishing miR-590 as a target for treatment of
cardiac pathologies consequent to cardiomyocyte loss (Eulalio et al., 2012).
Dysregulations of miR-590-3p and miR-590-5p have also been reported in bladder
cancer (Mo et al., 2013) and renal cell carcinoma (Xiao et al., 2013). However, the
expression profile and target genes of miR-590 in breast cancer and ovarian cancer
tumorigenesis and development of drug resistance have not been studied.
5.1.5 miR-370
miR-370 is located on chromosome 14q32.2 and participates in a myriad of biological
processes including regulation of lipid metabolism (Iliopoulos et al., 2010) and
development of coronary artery disease (Gao et al., 2012). Accumulating
investigations suggest a crucial role of miR-370 in the development of cancer. For
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example, overexpression of miR-370 has been reported in gastric carcinoma and
miR-370 contributes to carcinogenesis by down-regulating TGFβ-RII (Lo et al.,
2012). On the other hand, it has also been suggested that miR-370 could function as a
tumour suppressor by down-regulating FOXM1 (Feng et al., 2013; X. Zhang et al.,
2012).
In view of the emerging roles of miR-590 and miR-370 in tumorigenesis, a correlation
analysis was performed to determine if these miRNAs could have potential
interactions with FOXM1 implicated in the development of drug resistance in breast
and ovarian cancer cells. Interestingly, both miR-590 and miR-370 appeared to have
high correlation scores with FOXM1. It is thus tempting to investigate how miR-590
and miR-370 would interact with FOXM1 that might be implicated in the acquisition
of drug resistance in cancer cells.
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5.1.6 Aim:
1. To delineate the expression profiles of miR-590-5p, miR-590-3p and miR-370 in a
panel of chemosensitive and chemoresistant breast cancer and ovarian cancer cell
lines.
2. To identify candidate target genes of miR-590-5p.
3. To study potential interaction between FOXM1 and miR-590
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5.2 Materials and methods
5.2.1 Cell culture
Human breast cancer cell lines MCF-7 and MDA MB-231 were cultured in
Dulbecco's modified eagle medium (DMEM) (Gibco, UK) supplemented with 10%
foetal bovine serum (FBS) and 100 units/ml of penicillin-streptomycin (Invitrogen).
Breast cancer cell lines LCC9 and TAMR 4/7 were cultured in DMEM and DMEM
F-12 (Gibco) supplemented with 10% double charcoal stripped foetal bovine serum
(Globepharm Ltd.) respectively. Breast cancer cell lines MLET 1/2/5 cells were
cultures in DMEM lacking phenol red (DMEM-PR) (Gibco). Ovarian cancer cell lines
PEO1 and PEO1-TaxR were cultured in RPMI1640 (Sigma) supplemented with 10%
foetal bovine serum (FBS) and 100 units/ml penicillin-streptomycin (Invitrogen).
PEO1-TaxR is supplemented with 50nM of paclitaxel. All cell lines were maintained
at 37°C in humidified incubator with 5% CO2. Cell culture medium was changed
every 3 to 5 days depending on cell density. For routine passage, when cells reached
85% to 90% confluency, they were split at a ratio of 1:4.
5.2.2 RNA extraction and cDNA synthesis
Total RNA was extracted using miRNeasy Mini Kit (Qiagen) according to
manufacturer's instructions. Reverse transcription was carried out with miScript II RT
Kit (Qiagen) using HiFlex buffer to generate cDNA from total RNA and HiSpec
buffer to generate cDNA from miRNAs.
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5.2.3 Quantitative real-time PCR
Quantitative real-time PCR was performed using miScript SYBR Green PCR Kit
(Qiagen) for miRNA analysis and Power SYBR Green PCR Master Mix (Applied
Biosystems) for mRNA analysis. Reactions were run on ABI7900 Sequence
Detection System (Applied Biosystems). Housekeeping genes L19 and RNU6B were
used for normalization for mRNA and miRNA levels respectively. Primers used were
listed as follows:
Primer Forward 5' to 3' Reverse 5' to 3'
FOXM1 CGTTTCTGCTGTGATTCCAAG GCCAACCGCTACTTGACATT
FOXO3a TCTACGAGTGGATGGTGCGTT CGACTATGCAGTGACAGGTTGTG
FOXA1 GAAGATGGAAGGGCATGAAA GCCTGAGTTCATGTTGCAGA
FOXC1 AGTTCATCATGGACCGCTTC AGCCTGTCCTTCTCCTCCTT
FOXC2 AGTTCATCATGGACCGCTTC TCTCCTTGGACACGTCCTTC
Table 5.1. Primers used in the analysis of expressions of Forkhead box genes
5.2.4 Ectopic expression of hsa-miR-590-5p mimic
MCF-7 cells were transfected with hsa-miR-590-5P mimic (C-300914-01, Thermo
Scientific, UK) and non-specific control (NSC) (Dharmacon) using Oligofectamine
transfection reagent (Invitrogen) according to manufacturer's instructions.
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5.2.5 Western blot
Cells were harvested with lysis buffer [0.125 m Tris, pH 6.8 at 22°C containing 1%
NP-40 (v/v), 2 mM ethylenediamine tetraacetic acid (EDTA), 2 mM
N-ethylmaleimide, 2 mM phenylmethanesulphonyl fluoride (PMSF), 1 mM sodium
orthovanadate and 0.1 μm sodium okadate] and centrifuged at 4°C for 10 min. Protein
concentration was determined by detergent-compatible (DC) protein assay (Bio-Rad).
Twenty micrograms of protein were separated by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to
polyvinylidene difluoride membrane and hybridized with the following anti-bodies:
anti-FOXM1 (sc-502, Santa Cruz Biotechnology), anti-FOXO3a (sc-11351, Santa
Cruz Biotechnology), anti-FOXA1 (ab-55178, Abcam, UK), anti-FOXC1 (ab-24067,
Abcam), anti-FOXC2 (ab-ab65141, Abcam) and anti-β-tubulin (sc-9104, Santa Cruz
Biotechnology).
5.2.6 Transient knockdown of FOXM1
ON-TARGET Plus Human FOXM1 siRNA and Non-targeting Control siRNAs
(Thermo Scientific, CO, USA) were employed for transient silencing of FOXM1
using Oligofectamine transfection reagent (Invitrogen) as previously described.
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5.2.7  Luciferase reporter assay
MCF-7 cells seeded in 96-well plate were transfected FuGENE 6 Transfection
Reagent (Roche) with a mixture of pGL3-miR-590-3p ( a kind gift of Dr Caroline,
University Claude Bernard Lyon 1) renilla and an increasing amount (0, 5, 10, 25, 50,
100 ng) of pcDNA3-FOXM1. Luciferase activity was detected by steadylite plus
system (PerkinElmer, MA, USA) after 24 h. Briefly, one pot of luclite luciferase
reagent was mixed with 10ml of luclite buffer, 10μl of 1M MgCl2 and 5μl of 2M
CaCl2. The reagent mixture was diluted with equal volume of PBS and 100μl was
applied to each well. After incubating at RT for 15 min in darkness, cells were
transferred to opaque plate for measuring fluorescence activity. Afterwards, 25μl of
renlite reagent (0.5M HEPES pH7.8, 40mM EDTA, coelenterazine at 1mg/ml) was
added to each well and the plate was incubated at RT for 20 min in darkness followed
by measurement. Relative reading was obtained by dividing luciferase activity over
renilla activity.
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5.3 Results
5.3.1 General expression levels of hsa-miR-590-5p (miR-590-5p), hsa-miR-590-3p
(miR-590-3p) and hsa-miR-370 (miR-370) in a panel of breast cancer cell lines
and a pair of ovarian cancer cell line
Quantitative real-time PCR (qPCR) was employed to assess the endogenous
expression profiles of miR-590-5p, miR-590-3p and miR-370 in breast cancer cell
lines MCF7, MDA MB-231, LCC9 (steroidal antiestrogen ICI-resistant), TAMR4 and
TAMR7 (tamoxifen-resistant), MLET1, MLET2 and MLET5 (estrogen-deprived) as
well as ovarian cancer cell lines PEO1 and PEO1-TaxR (paclitaxel-resistant). MCF7
displayed low expression of miR-590-5p, miR-590-3p and miR-370 among the panel
of breast cancer cell lines, whereas LCC9, TAMR4 and TAMR7, MLET1, MLET2
and MLET5 harbored elevated expression of the miRNAs (P<0.05) (Figures 5.1-5.3).
Intriguingly, MDA MB-231 exhibited lowest expression of miR-590-5p, and the
levels of miR-590-3p and miR-370 were slightly higher than that of MCF7. Though
PEO1-TaxR showed reduced expression of miR-370 when compared to the sensitive
counterpart PEO1, no observable differences in the levels of miR-590-5p and
miR-590-3p were observed between PEO1 and PEO1-TaxR (Figures 5.1-5.3).
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Figure 5.1. qPCR analysis of the general expression level of miR-590-5p in a
panel of breast cancer and ovarian cancer cell lines. Housekeeping gene RNU6B
was used for normalization. Data represent triplicates from three experiments.
*P<0.05, **P=0.002, ***P<0.0005, ns: not significant.
Figure 5.2. qPCR analysis of the general expression level of miR-590-3p in a
panel of breast cancer and ovarian cancer cell lines. Housekeeping gene RNU6B
was used for normalization. Data represent triplicates from three experiments.
*P<0.05, **P<0.002, ns: not significant.
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Figure 5.3. qPCR analysis of the general expression level of miR-370 in a panel of
breast cancer and ovarian cancer cell lines. Housekeeping gene RNU6B was used
for normalization. Data represent triplicates from three experiments. *P<0.05,
**P<0.003, ***P<0.0005, ns: not significant.
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5.3.2 Identification of candidate target Forkhead box genes of miR-590-5p by
ectopic expression of hsa-miR-590-5p mimic
In order to identify candidate target forkhead box genes of miR-590-5p, transient
transfection of hsa-miR-590-5p mimic was applied to MCF7 harboring lowest
miRNA level. Interestingly, overexpression of miR-590-5p resulted in up-regulations
of FOXO3a and FOXC2 at mRNA level, though the increase in protein level was not
as obvious (Figure 5.4). On the other hand, both the transcript and protein levels of
FOXM1 appeared to be mildly reduced. The protein expression of FOXA1 was
down-regulated to a greater extent than that of the mRNA expression. There were no
obvious changes in the expression of FOXC1 upon ectopic expression of miR-590-5p
(Figure 5.4).
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Figure 5.4.  Left panel: Representative immunoblots of selected Forkhead box
targets of miR-590-5p after treatment with hsa-miR-590-5p mimic. NSC:
Non-specific control. Right panel: qPCR analysis of mRNA expressions of
corresponding Forkhead box genes after treatment with hsa-miR-590-5p mimic.
Housekeeping gene L19 was used for normalization. Data represent triplicates from
three experiments. *P=0.02, ns: not significant.
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5.3.3 Transient FOXM1 knockdown down-regulates miR-590-5p and miR-590-3p
FOXM1 silencing was used to determine if FOXM1 could regulate miR-590.
Quantitative real-time PCR showed the expressions of miR-590-5p and miR-590-3p
were down-regulated after transient FOXM1 knockdown (Figure 5.5), indicating
FOXM1 is capable of regulating the expression of miR-590.
Figure 5.5. Quantitative real-time PCR showing down-regulation of miR-5905p
and miR-590-3p after transient FOXM1 knockdown. Data represent triplicates
from three experiments. ns: not significant.
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5.3.4 FOXM1 is capable of activating the promoter of miR-590
Luciferase reporter assay was performed in an attempt to elucidate if FOXM1 could
transcriptionally regulate the expression of miR-590. Titration of pGL3-miR-590-3p
with increasing amounts of pcDNA-FOXM1 revealed a gradual rise in luciferase
reading, with an abrupt increase at 25ng of pcDNA-FOXM1 (Figure 5.6), indicating
FOXM1 could transcriptionally activate the expression of miR590.
Figure 5.6. Luciferase reporter assay demonstrating FOXM1 could
transcriptionally activate the expression of miR-590
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5.4 Discussion
Breast cancer is the second leading cause of cancer death in women accounting for
around 15% of all female cancer deaths. Although breast cancer mortality has been
decreasing, the development of chemoresistance is a perennial problem.
Accumulating evidence suggests that various cell types and human cancers display
distinct miRNA expression profiles, and that miRNAs may be implicated in a variety
of physiological and pathological processes including cell cycle progression, cell
differentiation, apoptosis, inflammation and tumorigenesis.
In addition to regulating cardiomyocyte proliferation in both neonatal and adult
animals (Eulalio et al., 2012), dysregulations of miR-590 have been documented in
bladder cancer and renal cell carcinoma (Mo et al., 2013; Xiao et al., 2013). Recently,
down-regulation of miR-590-5p was shown to be involved in hepatocellular
carcinoma and restoration of miR-590-5p could inhibit the growth of cancer cells
(Shan et al., 2013). In contrast, Chu et al demonstrated miR-590 possesses oncogenic
properties in that miR-590 is capable of promoting cervical cancer cell growth and
invasion by targeting Close Homologue of L1 (CHL1) (Chu et al., 2014). In the
current study, we found miR-590-5p and miR-590-3p may be involved in the
development of drug resistance in breast cancer cells. Quantitative real-time PCR
revealed overexpressions of miR-590-5p and miR-590-3p in ICI resistant cell line
LCC9 as well as tamoxifen resistant cell lines TAMR4 and TAMR7 when compared
to MCF7. Intriguingly, although up-regulation of miR-590-3p was observed in MDA
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MB-231, reduced expression of miR-590-5p was detected in MDA MB-231 as
compared with MCF7, implying differential roles of miR-590-5p and miR-590-3p in
MDA MB-231 which harbours mutations in TP53. Furthermore, ectopic expression of
miR-590-5p resulted in down-regulation of FOXM1 and FOXA1 at both transcript
and protein levels in MCF7, suggesting FOXM1 and FOXA1 might be candidate
downstream targets of miR-590. In view of the bioinformatics analysis revealing
miR-590 to be a potential transcriptional target of FOXM1, functional in vitro
experiments were performed. Transient knockdown of FOXM1 reduces the
expressions of miR-590-5p and miR-590-3p. FOXM1 is able to induce the activation
of promoter region of miR-590-3p as revealed by Luciferase reporter assay. Further
investigations are necessary to elucidate the mechanism by which miR-590
contributes to the acquisition of drug resistance in breast cancer as well as the role of
interaction between FOXM1 and miR-590.
Similarly, quantitative real-time PCR also showed up-regulation of miR-370 in LCC9,
TAMR4 and TAMR7 when compared to MCF7, suggesting a role of miR-370 in the
acquisition of chemoresistance in breast cancer. Interestingly, the expression of
miR-370 is also lower in paclitaxel resistant ovarian cancer cell line PEO1-TaxR than
the sensitive cell line PEO1. Given the recent finding that miR-370 may function as a
tumour suppressor in laryngeal squamous cell carcinoma (LSCC) through
down-regulation of FOXM1 (Yungang et al., 2014 ), it is tempting to carry out further
studies in order to delineate potential interactions between miR-370 with FOXM1 as
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well as other FOX proteins with emphasis on the role of miR-370 in the development
of breast and ovarian cancer. Potential interactions between miR-590 and miR-370
with KIF2C and PAK4 will also be pursued in further studies.
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Chapter 6
Discussion
6.1 Summary of findings
Ovarian carcinoma is the most lethal gynecological malignancy. Identifying novel
prognostic and therapeutic targets is therefore crucial for improving the long-term
survival rate of patients. Forkhead box protein M1 (FOXM1), which is a widely
studied member of the FOX superfamily of proteins, plays a vital role in a broad
spectrum of biological processes. Recently, overexpression of FOXM1 has been
documented in multiple human malignancies including cancers of lung, prostate and
breast. In this study, elevated nuclear FOXM1 expression was found to be
significantly associated with advanced stages of ovarian cancer. Though not reaching
statistical significance, FOXM1 overexpression also showed correlation with serous
histologic subtype, high grade cancers (poor differentiation) and chemoresistance.
Patients with a high FOXM1 level had a significantly shorter overall and disease-free
survival than those with low FOXM1 expression. Multivariate progression analysis
further established high expression of FOXM1, advanced cancer stages and poor
histological differentiation (high grade) as independent prognostic factors for short
overall and disease-free survival. Consistently, Transwell assays demonstrated
transient knockdown of FOXM1 was capable of reducing the migratory and invasive
abilities of ovarian cancer cells.
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Although FOXM1’s association with high grade ovarian cancer tumours has been
reported (Chan et al., 2012), whether FOXM1 contributes to the acquisition of
paclitaxel resistance in ovarian cancer remains unanswered. In view of the
immunohistochemical finding suggesting an association between FOXM1 and
chemoresistance, a pair of established paclitaxel-sensitive and -resistant ovarian
cancer cell lines were employed to investigate the effect of paclitaxel on FOXM1.
Intriguingly, paclitaxel treatment resulted in reduced expression of FOXM1 in
SKOV-3 but not in the resistant cell line SKOV3-TR, implicating a role of FOXM1 in
mediating paclitaxel resistance in ovarian cancer cells. Immunofluorescence study
further showed FOXM1 knockdown could enhance paclitaxel-mediated cell death in
two ovarian cancer cell lines. Western blot and flow cytometric analyses suggested
FOXM1 knockdown in the chemoresistant ovarian cancer cell line SKOV3-TR could
induce G2/M arrest and enhance paclitaxel-mediated mitotic catastrophe in a
p53-independent and Caspase-9-independent manner.
During recent years increasing attention has been directed towards the oncogenic
roles of KIF2C and PAK4. In this study, the expressions of KIF2C and PAK4 were
observed to alter in a similar pattern to FOXM1 expression upon paclitaxel treatment
by exhibiting reduced expression only in the paclitaxel sensitive cell line at later time
points. An analysis of immunohistochemical scores revealed a significant positive
correlation between nuclear FOXM1 expression and total PAK4 expression. FOXM1
silencing, qPCR, luciferase reporter assay and chromatin immunoprecipitation
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analyses confirmed KIF2C and PAK4 to be novel transcriptional targets of FOXM1.
Clonogenic assay and flow cytometry further demonstrated KIF2C contributes to the
acquisition of paclitaxel resistance in ovarian cancer cells.
Given the emerging roles of miRNAs in tumorigenesis and chemoresistance, it is
tempting to investigate if miRNAs contribute to the development of drug resistance in
breast and ovarian cancer cells. qPCR analysis revealed up-regulations of miR-590
and miR-370 in a panel of drug resistant breast cancer cell lines and a paclitaxel
resistant cell line. Overexpression of miR-590 resulted in reduced FOXM1 expression.
Interestingly, FOXM1 could also regulate the expression of miR-590 at transcriptional
level, suggesting a mutual regulation between FOXM1 and miR-590.
In summary, this study demonstrated overexpression of FOXM1 in ovarian cancer
correlated with poor patients' survival and acquisition of paclitaxel resistance. KIF2C
and PAK4 were identified as novel transcriptional targets of FOXM1 implicated in
chemoresistance. Although therapeutics targeting PI3K are being developed at a rapid
pace, the central role of PI3K in a large array of diverse biologic processes raises
concerns about its use in therapeutics (Courtney et al., 2010). Instead, FOXM1 may
emerge as a potential prognostic marker as well as a therapeutic target in ovarian
cancer. Thiazole antibiotics siomycin A and thiostrepton have been reported to act as
potent inhibitors of FOXM1 (Alvarez-Fernandez & Medema, 2013).
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6.2 Limitations
Although considerable evidence has been gathered regarding the association between
FOXM1 and clinicopathological parameters of ovarian cancer, recruitment of a larger
number of tissue samples for immunohistochemical study is necessary to determine if
a significant correlation exists between FOXM1 expression and chemoresistance. In
vivo studies involving nude mice could be performed to further validate the findings
of in vitro functional assays.
6.3 Plan for future study
Site-directed mutagenesis, generation of mutant reporter plasmids and luciferase
reporter assay will be pursued to validate if FOXM1 is able to activate the promoter
regions of KIF2C and PAK4. Overexpressions of KIF2C and PAK4 in FOXM1
knockout ovarian cancer cell lines will further shed light on how the interaction would
affect the migratory and invasive abilities as well as sensitivity to chemotherapeutic
drugs of cancer cells. Ovarian cancer cell lines with stable overexpression or
knockdown of FOXM1 and KIF2C will be generated and in vivo experiments
involving nude mice will be performed. In situ hybridization (ISH) will be performed
to determine the expression profiles of miR-590 and miR-370 in breast and ovarian
cancer clinical samples. Inhibitors of the miR-590 and miR-370 will be employed to
study the function of the miRNAs regarding chemoresistance and to identify novel
regulatory targets.
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